Legal status in United Arab Emirates

Per-substance legal status for United Arab Emirates, from sourced statutes where available. Legal information, not legal advice; drug laws change, so confirm with the destination’s embassy or drug authority before you travel.

69 confirmed substances19 not individually verifiedLast updated October 8, 2026

Confirmed legal status

2-FDCK

Legal status: 2-FDCK is placed at Schedule 6, item 3 of Decision No. 158 of 2025, the printed entry being «2-فلورو ديسكلوروكيتامين», and the dossier records that the schedule reaches it by its expanded name and chemical formula, rendering the chemical name as 2-(2-fluorophenyl)-2-(methylamino)cyclohexanone. The fluorine for chlorine substitution is the entire basis on which this compound is sold as distinct from ketamine, and the schedule has answered it by printing the fluoro compound in its own right at item 3 rather than leaving it to be argued into the ketamine entry at item 7 of the same schedule. So the two arylcyclohexylamines sit four items apart in the same schedule, each named. The row runs through Articles 11, 43 and 58, with Schedule 10 group 3 carrying the quantity band. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and this compound is at Schedule 6, item 3, so the article applies to the row. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary on this row rather than mandatory, which is the specific respect in which the Schedule 6 branch differs from the Schedule 1, 2, 4 Section I and 5 branch. The article states no quantity, and the Schedule 10 group 3 band that applies to this substance does not gate it. A capital route that is discretionary and quantity free is still a capital route, and neither the discretion nor the group 3 figure should be read as a threshold below which it disappears. Article 43 carries the personal use route for this branch, with no tariff stated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: 2-FDCK is at Schedule 6, item 3, a research chemical placement with no medicinal product behind it, in contrast to the ketamine entry at item 7 of the same schedule which does have a clinical use. No prescribing route or permit is recorded for it, so the medical question is deferred rather than borrowed from the neighbouring entry.
Documentation: No documentation route is recorded for 2-FDCK. Provenance: the entry «2-فلورو ديسكلوروكيتامين» at Schedule 6, item 3 was read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative rather than on the Schedule 10 group 3 band. The practical point is that the fluoro compound has its own item number, so a vendor's claim that it is not the scheduled anaesthetic is correct and irrelevant.

United Arab Emirates, Decision No. 158 of 2025, Schedule 6, item 3, printed entry «2-فلورو ديسكلوروكيتامين» for 2-FDCK, named in its own right rather than reached through the ketamine entry at item 7 of the same schedule · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 group 3 band does not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=2-%D9%81%D9%84%D9%88%D8%B1%D9%88%20%D8%AF%D9%8A%D8%B3%D9%83%D9%84%D9%88%D8%B1%D9%88%D9%83%D9%8A%D8%AA%D8%A7%D9%85%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English chemical rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

2-FDCK in United Arab Emirates, full detail →

25I-NBOMe

Legal status: 25I-NBOMe is named in the phenethylamines block of Schedule 5 of Decision No. 158 of 2025, at item 25, subitem 17. The entry is «25I-NBOMe؛ 2C-I-NBOMe», so the schedule carries the compound under both of the abbreviations it circulates as, and the dossier renders the accompanying chemical name as 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine. Naming the synonym matters on an N-benzyl row, because the point at which a 2C compound becomes an NBOMe compound is exactly where an analogue argument would otherwise be made, and here the schedule has named the product rather than left it to inference. Schedule 5 is the first psychotropic schedule, which is why this row runs through Articles 10, 41 and 57 rather than through the Schedule 6 to 8 branch, and Schedule 10 places it in group 1 for quantity purposes. The dossier states the content of Article 57 and does not state what Articles 10 and 41 provide. The placement was read on 20 September 2026.
Consequences if caught: Schedule 5 is one of the four schedule groups Article 57 names, and subitem 17 of the phenethylamines block is where this row sits inside it. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, so the capital route on this row is quantity free. Schedule 10 does place this substance in group 1, and group 1 is a real quantity band, but the dossier is explicit that the Schedule 10 bands do not gate the Article 57 route. That is the whole of the distinction worth carrying away: a group 1 figure answers a different question from the capital one, and reading it as the death threshold would invent a threshold the article does not contain. Article 41 is the personal use route the dossier attaches to this branch, with its tariff unstated.
If prescribed / medical: The dossier records at one row, modafinil, that a 268 entry ministry travellers list was checked and expressly not used as a schedule, so that list does not decide placement for anything. Attached to this substance: 25I-NBOMe is at Schedule 5, item 25, subitem 17, a psychotropic placement with no medicinal product behind it in the dossier's record. No prescribing route, exemption or permit procedure is given for it, and inventing one from the Schedule 5 branch would be an inference the dossier does not support, so the question is deferred.
Documentation: There is no medicine here to document. The dossier records 25I-NBOMe only as a scheduled psychotropic at Schedule 5, item 25, subitem 17, with no product, prescription or permit route attached to it, so no paperwork is described for this row. Provenance: the entry «25I-NBOMe؛ 2C-I-NBOMe» and the subitem 17 placement were read on 20 September 2026, and the capital analysis rests on Article 57 rather than on the group 1 quantity band.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, item 25 (phenethylamines), subitem 17, printed entry «25I-NBOMe؛ 2C-I-NBOMe» for 25I-NBOMe, with Articles 10, 41 and 57 the routes attached to this branch and Schedule 10 group 1 carrying a quantity band that does not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=25I-NBOMe and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English chemical rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

25I-NBOMe in United Arab Emirates, full detail →

2C-B

Legal status: 2C-B is placed in Schedule 6 of Decision No. 158 of 2025, the branch the dossier describes as the psychotropic Schedule II equivalent, at the printed entry «2C-B؛ 4-برومو-2،5-ثنائي ميثوكسي فينيثيل أمين». The entry pairs the abbreviation with the 4-bromo-2,5-dimethoxy phenethylamine description, and the dossier renders the chemical name as 4-bromo-2,5-dimethoxyphenethylamine. The placement is the fact that separates this row from its closest neighbours: the other 2C compounds in this table are carried in the Schedule 5 phenethylamines block, and this one is in Schedule 6, which sends it to Article 58 rather than to the harsher Article 57 group. That is a difference in article rather than in chemistry, and it is why the family name cannot be used to answer the row. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Article 58 is the provision that reaches Schedules 3, 6, 7 and 8, and 2C-B is in Schedule 6, so this is the row's capital route. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, which makes death discretionary here rather than mandatory, and that is the material difference from the Article 57 rows in the same instrument. Article 58 states no quantity, so the route is quantity free in the same way, and the Schedule 10 bands do not convert it into a threshold rule. Both halves of that have to be held at once: the exposure is capital and it is not mandatory, and neither half should be reported without the other. Article 43 carries the personal use route for this branch, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: 2C-B is in Schedule 6, and no medicinal product, research authorisation or prescribing route is recorded against that entry. The dossier gives Article 11 as the article attached to this branch without stating what it provides, so no authorisation procedure is described here and the medical question is deferred.
Documentation: No documentation route is recorded for 2C-B. Provenance: the Schedule 6 placement and the entry «2C-B؛ 4-برومو-2،5-ثنائي ميثوكسي فينيثيل أمين» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative rather than on the Schedule 10 bands. The point worth carrying is the schedule split inside the phenethylamine family: this compound is Schedule 6 and Article 58, while several of its close relatives in this table are Schedule 5 and Article 57.

United Arab Emirates, Decision No. 158 of 2025, Schedule 6 (psychotropic Schedule II equivalent), printed entry «2C-B؛ 4-برومو-2،5-ثنائي ميثوكسي فينيثيل أمين» for 2C-B, placed outside the Schedule 5 phenethylamines block that carries its relatives · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 bands do not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=2C-B and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English chemical rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

2C-B in United Arab Emirates, full detail →

2C-E

Legal status: 2C-E is expressly named in Schedule 5 of Decision No. 158 of 2025, in the phenethylamines block at item 25, subitem 3. The entry is «2C-E؛ 4-إيثيل-2،5-ثنائي ميثوكسي فينيثيل أمين», which pairs the short name with the 4-ethyl-2,5-dimethoxy description, and the dossier renders the chemical name as 2-(4-Ethyl-2,5-dimethoxyphenyl)ethanamine. The subitem number is the load bearing fact here: the phenethylamines block enumerates its members one by one, so 2C-E is controlled because it is printed, not because it shares a ring substitution pattern with other 2C compounds that are. Schedule 5 is the first psychotropic schedule, so the row runs through Articles 10, 41 and 57, and Schedule 10 assigns it to group 1 for quantity purposes. The dossier gives the content of Article 57 only. The placement was read on 20 September 2026.
Consequences if caught: Subitem 3 of the Schedule 5 phenethylamines block puts this row in one of the four schedule groups Article 57 names. For those groups the dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger, with no quantity stated anywhere in the article. Schedule 10 group 1 is a quantity band that applies to this substance, and the dossier records that it does not gate the Article 57 route, so the band and the capital route answer different questions and must not be read together. A row like this one is where the two get conflated most easily, because a group 1 figure exists and looks like a threshold. Article 41 carries the personal use route for this branch and the dossier does not state its tariff, so no term of years is given here.
If prescribed / medical: The dossier records at one row, modafinil, that a 268 entry ministry travellers list was checked and expressly not used as a schedule, which is the only country level traveller handle it gives. Attached to this substance: 2C-E is at Schedule 5, item 25, subitem 3, and no medicinal product, prescribing route or permit procedure is recorded against that entry. The question of whether any authorisation could exist for a Schedule 5 phenethylamine is not answered by the dossier and is deferred rather than reasoned out from the branch.
Documentation: No documentation route is recorded for 2C-E. The dossier carries the subitem 3 placement and nothing on the medical side, so there is no prescription, permit or declaration procedure to set out for this row. Provenance: the entry «2C-E؛ 4-إيثيل-2،5-ثنائي ميثوكسي فينيثيل أمين» and its position at item 25, subitem 3 were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 group 1 band.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, item 25 (phenethylamines), subitem 3, printed entry «2C-E؛ 4-إيثيل-2،5-ثنائي ميثوكسي فينيثيل أمين» for 2C-E, with Articles 10, 41 and 57 attached to this branch and Schedule 10 group 1 giving a quantity band that does not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=2C-E and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English chemical rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

2C-E in United Arab Emirates, full detail →

2C-I

Legal status: 2C-I is printed in Schedule 5 of Decision No. 158 of 2025, in the phenethylamines block at item 25, subitem 9. The entry «2C-I؛ 4-يودو-2،5-ثنائي ميثوكسي فينيثيل أمين» names the compound and its 4-iodo-2,5-dimethoxy description, and the dossier renders the chemical name as 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine. Subitem 9 should be read against subitem 17 of the same block, which carries 25I-NBOMe: the schedule controls the iodinated 2C compound and its N-benzyl derivative as two separate enumerated entries, so neither is reached through the other and a substance proved to be one is not answered with the placement of the other. Schedule 5 is the first psychotropic schedule, so this row runs through Articles 10, 41 and 57, with Schedule 10 group 1 carrying the quantity band. The placement was read on 20 September 2026.
Consequences if caught: Item 25, subitem 9 of Schedule 5 puts 2C-I inside one of the four schedule groups Article 57 names. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as naming no quantity, so nothing about weight has to be established for the capital route to be engaged on this row. Schedule 10 does give this substance a group 1 band, and the dossier records that the Schedule 10 bands do not gate Article 57, which means the band cannot be quoted as a death threshold without inventing a threshold the article does not contain. Article 41 is the personal use route the dossier attaches to this branch and its tariff is not stated, so no figure for personal possession is given here either.
If prescribed / medical: The dossier's single country level traveller handle is recorded at the modafinil row: a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: 2C-I is at Schedule 5, item 25, subitem 9, a research chemical placement with no medicinal product recorded behind it. No prescribing route, permit or exemption appears for it anywhere in the dossier, so the medical question is deferred rather than constructed from the schedule branch.
Documentation: Nothing is recorded that would document lawful carriage of 2C-I. The dossier holds the subitem 9 placement and no medical route at all, so this row has no prescription, permit or declaration procedure to describe. Provenance: the entry «2C-I؛ 4-يودو-2،5-ثنائي ميثوكسي فينيثيل أمين» at item 25, subitem 9 was read on 20 September 2026, and the capital analysis rests on Article 57 rather than on the group 1 band.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, item 25 (phenethylamines), subitem 9, printed entry «2C-I؛ 4-يودو-2،5-ثنائي ميثوكسي فينيثيل أمين» for 2C-I, distinct from subitem 17 which carries the N-benzyl derivative · Articles 10, 41 and 57 attach to this branch and Schedule 10 group 1 does not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=2C-I and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English chemical rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

2C-I in United Arab Emirates, full detail →

4-AcO-DMT

Legal status: 4-AcO-DMT is named in the tryptamines block of Schedule 5 of Decision No. 158 of 2025, at item 35, subitem 7. The entry is «4-AcO-DMT؛ 4-أسيتوكسي-N,N-ثنائي ميثيل تريبتامين», which carries both the abbreviation and the expanded 4-acetoxy form of the name, and the dossier renders the chemical name as 3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl acetate. The expanded name is what closes the row: an acetate ester of a controlled tryptamine would otherwise be the classic place to argue that the parent entry does not reach it, and here the schedule prints the ester itself. The tryptamines block sits in Schedule 5, the first psychotropic schedule, so the row runs through Articles 10, 41 and 57 with Schedule 10 group 1 carrying the quantity band. The dossier states the content of Article 57 and not of Articles 10 and 41. The placement was read on 20 September 2026.
Consequences if caught: Item 35, subitem 7 of Schedule 5 places 4-AcO-DMT in one of the four schedule groups Article 57 names. The dossier records that article as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, so on this row the capital exposure is a function of conduct and schedule and not of weight. Schedule 10 assigns a group 1 band to the substance, and the dossier records that those bands do not gate the Article 57 route, so the two must be kept apart. The practical consequence is that there is no amount below which the capital route is unavailable on this row, which is a materially different statement from a threshold being high. Article 41 carries the personal use route for this branch with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule, and that is the whole of the country level traveller material it carries. Attached to this substance: 4-AcO-DMT is at Schedule 5, item 35, subitem 7, and nothing in the dossier records a medicinal form, a prescribing route or a permit for it. The medical question is therefore deferred, not answered from the branch.
Documentation: No documentation route exists to describe for 4-AcO-DMT on this record. The dossier carries the subitem 7 tryptamine placement and no medical or permit material, so there is no paperwork that would make carriage lawful. Provenance: the entry «4-AcO-DMT؛ 4-أسيتوكسي-N,N-ثنائي ميثيل تريبتامين» at item 35, subitem 7 was read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 group 1 band.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, item 35 (tryptamines), subitem 7, printed entry «4-AcO-DMT؛ 4-أسيتوكسي-N,N-ثنائي ميثيل تريبتامين» for 4-AcO-DMT, the expanded 4-acetoxy name printed alongside the abbreviation · Articles 10, 41 and 57 attach to this branch and the Schedule 10 group 1 band does not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=4-AcO-DMT and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English chemical rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

4-AcO-DMT in United Arab Emirates, full detail →

4-HO-MET

Legal status: 4-HO-MET is named in the tryptamines block of Schedule 5 of Decision No. 158 of 2025, at item 35, subitem 12. The entry is «4-HO-MET؛ 4-هيدروكسي-N-ميثيل-N-إيثيل تريبتامين», and the dossier records that the schedule carries both the abbreviation and the 4-Hydroxy MET form, rendering the chemical name as 3-{2-[Ethyl(methyl)amino]ethyl}-1H-indol-4-ol. Subitem 12 is two places along from subitem 7, which carries the acetate ester 4-AcO-DMT, so the block is enumerating individual hydroxy and acetoxy tryptamines rather than controlling a family by description. That is what makes the placement usable: it rests on a printed name and not on a structural argument about the 4-position. Schedule 5 puts the row in the Articles 10, 41 and 57 branch, with a Schedule 10 group 1 quantity band. The placement was read on 20 September 2026.
Consequences if caught: Item 35, subitem 12 of Schedule 5 is inside one of the four schedule groups Article 57 names. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger, and as stating no quantity, so the capital route on this row is not reached by crossing a weight. Schedule 10 gives the substance a group 1 band, and the dossier is explicit that the Schedule 10 bands do not gate the Article 57 route. Anyone reading a group 1 figure as the point at which death becomes available on this row has substituted a threshold rule for a schedule rule, and the article does not contain the threshold. Article 41 is the personal use route the dossier attaches to this branch, with no tariff stated.
If prescribed / medical: The single country level traveller fact the dossier carries is recorded at the modafinil row: a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: 4-HO-MET is at Schedule 5, item 35, subitem 12, with no medicinal product, prescribing route or import permit recorded against it. The medical carriage question is deferred rather than inferred from the Schedule 5 branch.
Documentation: Nothing in the dossier documents a lawful route for 4-HO-MET, so no paperwork is set out for this row. What is recorded is the placement itself, which is the fact that governs. Provenance: the entry «4-HO-MET؛ 4-هيدروكسي-N-ميثيل-N-إيثيل تريبتامين» at item 35, subitem 12 was read on 20 September 2026, and the capital analysis for the row rests on Article 57 and not on the group 1 band.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, item 35 (tryptamines), subitem 12, printed entry «4-HO-MET؛ 4-هيدروكسي-N-ميثيل-N-إيثيل تريبتامين» for 4-HO-MET, the dossier also recording the 4-Hydroxy MET form · Articles 10, 41 and 57 attach to this branch and the Schedule 10 group 1 band does not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=4-HO-MET and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English chemical rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

4-HO-MET in United Arab Emirates, full detail →

5-MeO-DMT (Bufo / Toad)

Legal status: 5-MeO-DMT is listed expressly in the tryptamines block of Schedule 5 of Decision No. 158 of 2025, at item 35, subitem 14. The entry is «5-MeO-DMT؛ 5-ميثوكسي-N,N-ثنائي ميثيل تريبتامين», and the dossier renders the chemical name as 2-(5-Methoxy-1H-indol-3-yl)-N,N-dimethylethanamine. The methoxy position is printed in the entry itself, which separates this row from the plain dimethyltryptamine entry carried elsewhere in the same schedule: the two are distinct enumerated substances and the placement of one is not evidence about the other. There is no plant or secretion limb in the entry, so what is controlled is the compound by name. Schedule 5 puts the row in the Articles 10, 41 and 57 branch, with a Schedule 10 group 1 quantity band. The placement was read on 20 September 2026.
Consequences if caught: Subitem 14 of the Schedule 5 tryptamines block sits in one of the four schedule groups Article 57 names. The dossier records the article as stating mandatory death for its trafficking or promotion trigger and as stating no quantity at all, so the capital route on this row attaches to the schedule rather than to an amount. Schedule 10 supplies a group 1 band for this substance and the dossier records that the bands do not gate Article 57, so the band describes something other than capital exposure. The row therefore cannot be answered with a weight in either direction, neither a figure above which death becomes available nor one below which it does not. Article 41 is the personal use route attached to this branch and the dossier does not state its tariff.
If prescribed / medical: The dossier's country level traveller material is a single record at the modafinil row: a 268 entry ministry travellers list checked and expressly not used as a schedule. Attached to this substance: 5-MeO-DMT is at Schedule 5, item 35, subitem 14, and the dossier carries no medicinal form, prescribing route or permit against that entry. The medical question is deferred here and not reasoned out from the branch or from the substance's research profile.
Documentation: No lawful carriage route is recorded for 5-MeO-DMT, so there is no document set to describe for this row. Provenance: the entry «5-MeO-DMT؛ 5-ميثوكسي-N,N-ثنائي ميثيل تريبتامين» at item 35, subitem 14 was read on 20 September 2026, and the capital analysis for the row rests on Article 57 and not on the Schedule 10 group 1 band. A traveller carrying anything said to contain this compound is outside what the dossier documents.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, item 35 (tryptamines), subitem 14, printed entry «5-MeO-DMT؛ 5-ميثوكسي-N,N-ثنائي ميثيل تريبتامين» for 5-MeO-DMT, a separate enumerated entry from the dimethyltryptamine entry in the same schedule · Articles 10, 41 and 57 attach to this branch and the Schedule 10 group 1 band does not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=5-MeO-DMT and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English chemical rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

5-MeO-DMT (Bufo / Toad) in United Arab Emirates, full detail →

6-APB

Legal status: 6-APB is named in the phenethylamines block of Schedule 5 of Decision No. 158 of 2025, at item 25, subitem 29. The entry is «6-APB؛ 1-(1-بنزوفوران-6-يل)بروبان-2-أمين», which prints the benzofuran ring position alongside the abbreviation, and the dossier renders the chemical name as 1-(1-Benzofuran-6-yl)propan-2-amine. The position number is the whole of the identification problem on this row: benzofuran amphetamines differ from one another only in which ring carbon carries the side chain, so an entry that prints the 6 position is naming one isomer and a substance proved to be a different one is not answered by it. Schedule 5 places the row in the Articles 10, 41 and 57 branch, with a Schedule 10 group 1 quantity band. The placement was read on 20 September 2026.
Consequences if caught: Item 25, subitem 29 of Schedule 5 puts this row in one of the four schedule groups Article 57 names. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as naming no quantity, so identity rather than weight is what decides exposure. That makes the isomer question in the entry the decisive forensic fact on this row, because the capital route follows from being the printed substance and not from carrying an amount. Schedule 10 assigns a group 1 band, and the dossier records that the bands do not gate the Article 57 route, so the band is not a death threshold. Article 41 carries the personal use route for this branch with its tariff unstated.
If prescribed / medical: The dossier's only country level traveller record sits at the modafinil row, where a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: 6-APB is at Schedule 5, item 25, subitem 29, with no medicinal product or prescribing route recorded against it. No permit procedure is described and none is inferred, so the medical question is deferred.
Documentation: There is no medical route recorded for 6-APB and therefore no documentation to set out. Provenance: the entry «6-APB؛ 1-(1-بنزوفوران-6-يل)بروبان-2-أمين» at item 25, subitem 29 was read on 20 September 2026, and the capital analysis rests on Article 57 rather than on the Schedule 10 group 1 band. Because the entry identifies a single benzofuran isomer, any question about a related compound needs the analysis run again on that compound rather than borrowed from this row.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, item 25 (phenethylamines), subitem 29, printed entry «6-APB؛ 1-(1-بنزوفوران-6-يل)بروبان-2-أمين» for 6-APB, the entry naming the 6 position of the benzofuran ring · Articles 10, 41 and 57 attach to this branch and the Schedule 10 group 1 band does not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=6-APB and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English chemical rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

6-APB in United Arab Emirates, full detail →

Adderall

Legal status: Adderall is a brand and not a schedule heading, so Decision No. 158 of 2025 does not carry it as such. The dossier resolves the row through the product's content, recording the entry as «أمفيتامين؛ أملاح الأمفيتامين في Adderall»: the mixed amphetamine salts place a genuine product in the amphetamine regime, which in this instrument is Schedule 6. The consequence is that the placement follows the active ingredient rather than the label, so a prescription naming the brand is describing a Schedule 6 substance whether or not the schedule uses the brand word anywhere. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and the amphetamine content places this row in Schedule 6, so the article applies through the constituent rather than through a brand entry. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary here and not mandatory, and it records that the article states no quantity. The Schedule 10 bands do not gate that route. The combination that catches people on this row is a lawfully prescribed stimulant meeting a capital trafficking article, where the supply act most likely to arise is sharing tablets with someone else rather than anything a reader would call trafficking. Article 43 carries the personal use route for this branch, with its tariff unstated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: the product is placed through its amphetamine content in Schedule 6, and the dossier records no prescribing route, traveller allowance or import permit procedure for that branch. This is the row where the gap bites hardest, because the medicine is prescribed routinely to people who travel, and the dossier does not record what an Emirati authorisation would require. The question is deferred rather than answered.
Documentation: Carry the prescription naming the active ingredient rather than only the brand, with the original dispensing packaging and a physician's letter, and settle the permit question with the health ministry before travelling, because no Emirati permit procedure is recorded in this dossier. Provenance: the placement through amphetamine content and the entry «أمفيتامين؛ أملاح الأمفيتامين في Adderall» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative. A brand name alone does not disclose what is in the box, and it is the content that the schedule reaches.

Federal Decree-Law No. 30 of 2021, Table 5 (capital for trafficking) · uaelegislation.gov.ae · Federal Decree-Law No. 30 of 2021 carries the tables this cell reads against. This project's United Arab Emirates substance dossier checked on 20 September 2026 records that the official legislation portal record stayed behind a web application firewall and that the tables were read from a Sharjah Health Authority republication whose own version is not dated there, so no version of the tables is established. That does not rule out a later amendment made or commenced since. · Updated September 21, 2026

Adderall in United Arab Emirates, full detail →

Alcohol

Legal status: Alcohol is not a narcotic or psychotropic entry in Decision No. 158 of 2025. The dossier ran a completed non reach search across Schedules 1 to 9 for «الكحول؛ الإيثانول؛ الكحول الإيثيلي», that is alcohol, ethanol and ethyl alcohol, and recorded that none of them appears as a narcotic or psychotropic entry. What governs instead is the separate federal alcohol and licensing regime. The dossier is careful about what that finding is and this cell keeps the same limit: a completed non reach search plus the existence of a separate licensing regime is a verified finding about which regime applies, and it is not a finding that anything is permitted. The terms of the licensing regime are not recorded in the dossier, so nothing is stated here about who may buy, hold or consume, or where. The search was run on 20 September 2026.
Consequences if caught: Capital exposure: none. Decision No. 158 of 2025 Schedules 1 to 8 do not reach alcohol, so Articles 57 and 58 do not attach to it and there is no narcotics quantity to state. That is a statement about the drug law only. The separate alcohol and licensing regime carries its own sanctions, the dossier does not record what they are, and a sanction under that regime would not be a narcotics capital provision in any event. The practical exposure for a traveller therefore sits entirely outside the schedules that govern every other row in this table, and it cannot be estimated from them.
If prescribed / medical: There is no prescription question here in the sense the other rows in this table have one, because alcohol is outside Decision No. 158 of 2025 and there is no narcotics authorisation to obtain or to be refused. The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule, and alcohol does not turn on that list either. Anything a traveller needs to know here belongs to the licensing regime rather than to the drug law, and the dossier does not record its terms.
Documentation: Nothing in the drug law documentation set applies to alcohol. What would matter is whatever the federal alcohol and licensing regime requires, and the dossier does not record it, so this cell states the gap rather than filling it. Provenance: the completed Schedules 1 to 9 non reach search on alcohol, ethanol and ethyl alcohol was run on 20 September 2026. A traveller should treat the licensing rules, including any that vary between emirates, as the live question and establish them from a current official source rather than from a drug schedule.

United Arab Emirates, Decision No. 158 of 2025, completed Schedules 1 to 9 non reach search for «الكحول؛ الإيثانول؛ الكحول الإيثيلي», alcohol, ethanol and ethyl alcohol, returning no narcotic or psychotropic entry, with the separate federal alcohol and licensing regime governing instead and its terms not recorded in the dossier · the schedules were read at https://sha.shj.ae/#:~:text=%D8%A7%D9%84%D8%AC%D8%AF%D8%A7%D9%88%D9%84%20%D8%A7%D9%84%D9%85%D8%B1%D9%81%D9%82%D8%A9 and the federal instrument at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%83%D8%AD%D9%88%D9%84, the federal legislation portal · the instrument is written in Arabic and the English renderings are the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Alcohol in United Arab Emirates, full detail →

Amanita muscaria

Legal status: Amanita muscaria is not treated as a named narcotic in Decision No. 158 of 2025. The dossier resolves the row through a conduct based provision instead, recording Article 12(2) together with Article 44 and quoting the provision as «أية مادة أو نبات من غير المواد المخدرة أو المؤثرات العقلية... يكون من شأنها إحداث التخدير أو أي أثر آخر ضار بالعقل», which reaches any substance or plant other than the narcotics and psychotropic substances that is capable of causing intoxication or another effect harmful to the mind. The name «أمانيتا موسكاريا» was searched and the mushroom was not found as an entry. So the control here is functional rather than by listing: it depends on the purpose of the possession or use, and a mushroom held for another purpose is not placed by this route at all. The dossier's record was read on 20 September 2026.
Consequences if caught: Capital exposure: none. This row is reached through Articles 12(2) and 44 rather than by a Schedule 1 to 8 placement, Article 44 is non capital, Articles 57 and 58 do not attach, and no capital quantity applies. The structure is worth stating carefully, because a functional rule and a schedule placement fail in opposite directions: a schedule placement is decided by identity and reaches the substance whatever it was for, while this route turns on the purpose of intoxication or harm to the mind, so possession for that purpose is what brings it into play. The dossier does not state Article 44's tariff, so no figure is given here, and what is established is the route and its non capital character rather than the penalty.
If prescribed / medical: There is no prescription route here, and not because one was refused. Amanita muscaria has no schedule entry, so there is no placement for a prescription or a permit to attach to, and the provision that can reach it is a conduct rule rather than a licensing rule. The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule, which does not bear on this row. Nothing in the dossier records a medicinal or supplement route for this mushroom.
Documentation: No documentation route is recorded for Amanita muscaria, and none would be expected on a conduct based route, since what matters there is the purpose rather than the paperwork. Provenance: the Article 12(2) and Article 44 route and the name search «أمانيتا موسكاريا» were read on 20 September 2026. The practical point is that a dried mushroom product sold abroad as a supplement or a curiosity is not placed by a schedule here, and is also not thereby outside the law, because the applicable rule looks at what it is held for.

United Arab Emirates, Decision No. 158 of 2025 carries no Amanita muscaria entry · the row is reached, if at all, through the conduct based control at Article 12(2) with Article 44, quoted by the dossier as «أية مادة أو نبات من غير المواد المخدرة أو المؤثرات العقلية... يكون من شأنها إحداث التخدير أو أي أثر آخر ضار بالعقل», any substance or plant other than the narcotics and psychotropic substances capable of causing intoxication or another effect harmful to the mind, the name searched being «أمانيتا موسكاريا» · Article 44 is non capital and Articles 57 and 58 do not attach · read at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A3%D9%8A%D8%A9%20%D9%85%D8%A7%D8%AF%D8%A9%20%D8%A3%D9%88%20%D9%86%D8%A8%D8%A7%D8%AA%20%D9%85%D9%86%20%D8%BA%D9%8A%D8%B1%20%D8%A7%D9%84%D9%85%D9%88%D8%A7%D8%AF%20%D8%A7%D9%84%D9%85%D8%AE%D8%AF%D8%B1%D8%A9%20%D8%A3%D9%88%20%D8%A7%D9%84%D9%85%D8%A4%D8%AB%D8%B1%D8%A7%D8%AA%20%D8%A7%D9%84%D8%B9%D9%82%D9%84%D9%8A%D8%A9, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Amanita muscaria in United Arab Emirates, full detail →

Amphetamine

Legal status: Amphetamine is placed in Schedule 6 of Decision No. 158 of 2025, the psychotropic Schedule II equivalent branch, at the printed entry «أمفيتامين». The dossier's finding is that this placement, not a narcotic one, is what puts the row on Article 58 for trafficking rather than on Article 57. The same entry is also the route by which the mixed amphetamine salts product in this table is placed, so it is doing double duty: it carries the substance itself and it supplies the answer for a branded medicine that contains it. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The dossier states the content of Article 58 and does not state what Articles 11 and 43 provide. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and amphetamine is in Schedule 6, so the article applies to this row. The dossier records it as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary here where Article 57 is recorded as mandatory for the other schedule group, and it records that Article 58 states no quantity. The Schedule 10 bands do not gate that route. The point to hold is that the discretionary wording is the only softening there is: the article is still capital and it still contains no threshold, so a quantity based expectation is wrong in both directions on this row. Article 43 carries the personal use route for this branch, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: amphetamine is in Schedule 6, and the entry reaches prescribed amphetamine products through their content as well as the substance itself. The dossier records no prescribing route, traveller allowance or permit procedure for the Schedule 6 branch, so the medical question is deferred rather than answered.
Documentation: Carry the prescription naming amphetamine as the active ingredient, with the original dispensing packaging and a physician's letter, and put the permit question to the health ministry before travelling, because no Emirati procedure is recorded in the dossier. Provenance: the Schedule 6 placement and the entry «أمفيتامين» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative rather than on the Schedule 10 bands.

United Arab Emirates, Decision No. 158 of 2025, Schedule 6 (psychotropic Schedule II equivalent), printed entry «أمفيتامين» for amphetamine, the same entry supplying the route for products placed through their amphetamine content · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated where Article 57 is recorded as mandatory for the other schedule group, and the Schedule 10 bands do not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%A3%D9%85%D9%81%D9%8A%D8%AA%D8%A7%D9%85%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Amphetamine in United Arab Emirates, full detail →

Amyl Nitrite

Legal status: Amyl nitrite was not established as a Schedule 1 to 8 substance in Decision No. 158 of 2025; the name «نتريت الأميل» was searched and no placement was found. The dossier resolves the row instead through the conduct based control at Article 12(2) with Article 44, quoting «أية مادة أو نبات من غير المواد المخدرة أو المؤثرات العقلية... يكون من شأنها إحداث التخدير أو أي أثر آخر ضار بالعقل», any substance or plant other than the narcotics and psychotropic substances capable of causing intoxication or another effect harmful to the mind. That provision can reach an otherwise unscheduled inhalant when it is used or possessed for the purpose of intoxication or harmful mental effect. Amyl nitrite also has a recognised clinical history, so the purpose element is doing real work on this row rather than being a formality. The record was read on 20 September 2026.
Consequences if caught: Capital exposure: none. This row is reached through Articles 12(2) and 44 rather than by a Schedule 1 to 8 placement, Article 44 is non capital, Articles 57 and 58 do not attach, and no capital quantity applies. What the route does turn on is purpose, so the same bottle can be inside or outside it depending on why it is held, which is the opposite of how every scheduled row in this table works. The dossier does not state Article 44's tariff, so no penalty figure is given here. The absence of a schedule placement is a finding about the schedules and not a statement that the substance is unregulated.
If prescribed / medical: There is no schedule placement for amyl nitrite and therefore no narcotics authorisation to obtain or to be refused. The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule, which does not affect this row. Whether a medicinal amyl nitrite preparation is regulated as a medicine here is a question for the medicines regime rather than for the drug schedules, and the dossier does not record it.
Documentation: No documentation route is recorded for amyl nitrite. Provenance: the name search «نتريت الأميل» and the Article 12(2) with Article 44 route were read on 20 September 2026. The practical point is that the applicable rule looks at the purpose of possession rather than at a listing, so a product's packaging, its description as a room odouriser or its lawful sale elsewhere does not settle the question either way.

United Arab Emirates, Decision No. 158 of 2025 carries no amyl nitrite entry after the name search «نتريت الأميل» · the row is reached, if at all, through the conduct based control at Article 12(2) with Article 44, quoted by the dossier as «أية مادة أو نبات من غير المواد المخدرة أو المؤثرات العقلية... يكون من شأنها إحداث التخدير أو أي أثر آخر ضار بالعقل» · Article 44 is non capital and Articles 57 and 58 do not attach · read at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A3%D9%8A%D8%A9%20%D9%85%D8%A7%D8%AF%D8%A9%20%D8%A3%D9%88%20%D9%86%D8%A8%D8%A7%D8%AA%20%D9%85%D9%86%20%D8%BA%D9%8A%D8%B1%20%D8%A7%D9%84%D9%85%D9%88%D8%A7%D8%AF%20%D8%A7%D9%84%D9%85%D8%AE%D8%AF%D8%B1%D8%A9%20%D8%A3%D9%88%20%D8%A7%D9%84%D9%85%D8%A4%D8%AB%D8%B1%D8%A7%D8%AA%20%D8%A7%D9%84%D8%B9%D9%82%D9%84%D9%8A%D8%A9, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Amyl Nitrite in United Arab Emirates, full detail →

Ayahuasca

Legal status: Ayahuasca has no entry of its own in Decision No. 158 of 2025. The dossier resolves the row through the brew's constituent: the entry it relies on is «ثنائي ميثيل تريبتامين؛ DMT في الأياهواسكا», the Schedule 5 dimethyltryptamine entry, and the route is that a brew actually containing that Schedule 5 substance is reached through the constituent. The consequence is that the ritual or street name decides nothing here and the proved composition decides everything, so a preparation said to be ayahuasca which is not proved to contain the scheduled tryptamine has not been placed by this analysis, and one that is proved to contain it is placed exactly where the tryptamine sits. Schedule 5 puts the constituent in the Articles 10, 41 and 57 branch, alongside the Schedule 10 bands. The placement was read on 20 September 2026.
Consequences if caught: The capital route on this row belongs to the constituent, not to the label: where the brew is proved to contain the Schedule 5 tryptamine, Schedule 5 is one of the four groups Article 57 names, and the dossier records that article as stating mandatory death for its trafficking or promotion trigger with no quantity stated. Read carefully, that means the exposure turns on proof of composition and then attaches without any threshold at all, which is a harsher structure than a weight based rule and not a softer one. The Schedule 10 bands do not gate the Article 57 route, so no amount of brew is a safe amount once the constituent is proved. Where composition is not proved, this row states no capital route, because there is no ayahuasca entry to attach one to. Article 41 carries the personal use route for the constituent's branch with its tariff unstated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule, which is the only country level traveller handle it gives. Attached to this substance: ayahuasca is not itself scheduled and the placement relied on belongs to the dimethyltryptamine entry in Schedule 5, so there is nothing to which a prescription could attach in the first place. No religious, ceremonial or research exemption is recorded in the dossier, and none is inferred here.
Documentation: There is no document that would make a brew containing the scheduled tryptamine lawful to carry on this record, and no exemption for ceremonial use is recorded. Provenance: the constituent entry «ثنائي ميثيل تريبتامين؛ DMT في الأياهواسكا» and the Schedule 5 route were read on 20 September 2026. The one practical point worth carrying is that this row is decided by what a laboratory finds in the liquid and not by what the liquid is called, so a declaration naming it as a plant preparation does not change where it sits.

United Arab Emirates, Decision No. 158 of 2025, no ayahuasca entry · the row is resolved through the Schedule 5 constituent at the printed entry «ثنائي ميثيل تريبتامين؛ DMT في الأياهواسكا», with Articles 10, 41 and 57 attached to that branch and the Schedule 10 bands not gating Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%AB%D9%86%D8%A7%D8%A6%D9%8A%20%D9%85%D9%8A%D8%AB%D9%8A%D9%84%20%D8%AA%D8%B1%D9%8A%D8%A8%D8%AA%D8%A7%D9%85%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Ayahuasca in United Arab Emirates, full detail →

Benzodiazepines

Legal status: Benzodiazepines is a class label, and the member by member check that answers such a label was run against the Emirati schedules and returned members. Decision No. 158 of 2025 prints the six members carried in this table separately in Schedule 8, recorded at «ألبرازولام؛ كلونازيبام؛ ديازيبام؛ لورازيبام؛ إيتزولام؛ نيميتازيبام», which is alprazolam, clonazepam, diazepam, lorazepam, etizolam and nimetazepam. That is what makes this class label resolvable here: every member has its own printed entry and its own row in this table, so the class answer is the sum of six individual placements rather than a rule about the family. All six land in the same schedule, so the article result does not vary between them, but the reason it does not vary is that each was checked and not that a class rule was applied. A benzodiazepine the schedule does not name is not placed by this row. The row runs through Articles 11, 43 and 58. The placements were read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and all six named members sit in Schedule 8, so the article reaches the class through its members. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary rather than mandatory, and it records that the article states no quantity. The Schedule 10 bands do not gate that route. The finding worth stating plainly is that the lowest psychotropic schedule in this instrument is still inside a capital trafficking article, so the ordinariness of these medicines does not put them outside it. Article 43 carries the personal use route for this branch, with no tariff stated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this class: the placement that matters belongs to the identified member, and the six the schedule names are alprazolam, clonazepam, diazepam, lorazepam, etizolam and nimetazepam, so a prescription has to name one of those rather than the family word for there to be a placement to evidence at all. No prescribing route, traveller allowance or permit procedure is recorded for the Schedule 8 branch, so the question is deferred.
Documentation: Carry the prescription naming the individual benzodiazepine rather than the class, with the original dispensing packaging, because the entry that can be evidenced is the member's and not the family word's. Provenance: the six Schedule 8 member entries were read on 20 September 2026, and the capital analysis rests on Article 58 and its death or life alternative. If a traveller carries a benzodiazepine that is not one of those six, this row does not answer the question and that member needs checking against the schedule in its own right.

United Arab Emirates, Decision No. 158 of 2025, Schedule 8, resolved member by member for the benzodiazepines class · the members the schedule names are recorded at «ألبرازولام؛ كلونازيبام؛ ديازيبام؛ لورازيبام؛ إيتزولام؛ نيميتازيبام», namely alprazolam, clonazepam, diazepam, lorazepam, etizolam and nimetazepam, each with its own row in this table · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%A3%D9%84%D8%A8%D8%B1%D8%A7%D8%B2%D9%88%D9%84%D8%A7%D9%85 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English renderings are the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Benzodiazepines in United Arab Emirates, full detail →

Buprenorphine

Legal status: Buprenorphine is placed in Schedule 7 of Decision No. 158 of 2025, the branch the dossier describes as the psychotropic Schedule III equivalent, at the printed entry «بوبرينورفين». The dossier records the placement as standing despite the substance's recognised medical use for opioid dependence and for pain, which is the whole of the tension on this row: the medicine that treats dependence on Schedule 1 opioids is itself scheduled, though in the psychotropic branch rather than with them. That split placement is worth noting against the methadone row in the same table, which is in Schedule 1 and therefore on a different article. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and buprenorphine is in Schedule 7, so the article applies to this row. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary here, where the methadone row's Schedule 1 placement puts it on Article 57's mandatory wording instead. That is a real difference between two substitution medicines in the same instrument and it follows entirely from which schedule each sits in. Article 58 states no quantity, and the Schedule 10 bands do not gate it, so neither medicine's route is a threshold route. Article 43 carries the personal use provision for this branch, with its tariff unstated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: buprenorphine is in Schedule 7, and although the dossier acknowledges its recognised medical use it records no prescribing route, no traveller allowance and no permit procedure for it. A patient on a maintenance or pain regimen therefore has no recorded procedure to follow, and that gap is stated here rather than filled with an inference from the substance's clinical standing.
Documentation: Carry the prescription, the original dispensing packaging and a letter from the prescribing service naming the patient, the dose and the treatment period, and put the permit question to the health ministry before travelling because none is recorded in the dossier. Provenance: the Schedule 7 placement and the entry «بوبرينورفين» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative. Patch, tablet and film presentations are all the same active ingredient for the purposes of the entry.

United Arab Emirates, Decision No. 158 of 2025, Schedule 7 (psychotropic Schedule III equivalent), printed entry «بوبرينورفين» for buprenorphine, a psychotropic placement distinct from the Schedule 1 placement of methadone in the same instrument · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 bands do not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%A8%D9%88%D8%A8%D8%B1%D9%8A%D9%86%D9%88%D8%B1%D9%81%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Buprenorphine in United Arab Emirates, full detail →

Caffeine

Legal status: Caffeine is not a narcotic or psychotropic schedule entry in the current federal drug law materials. The dossier ran a completed non reach search across Schedules 1 to 9 of Decision No. 158 of 2025 for «الكافيين» and recorded no entry, and it draws the specific conclusion that ordinary caffeine products are therefore not assigned a Schedule 10 drug penalty. What governs instead is the food and medical product regime, whose terms the dossier does not record. The finding is about which body of law applies and not about any product being approved, so nothing here says that a particular caffeine product, a supplement or a concentrated preparation is permitted for sale or import. The search was run on 20 September 2026.
Consequences if caught: Capital exposure: none. Decision No. 158 of 2025 Schedules 1 to 8 do not reach caffeine, so Articles 57 and 58 do not attach and no narcotics quantity applies to it. The dossier's conclusion runs one step further on this row than on the others in its family: because there is no schedule placement, there is also no Schedule 10 band, so a caffeine product has no drug penalty quantity of any kind attached to it. Any consequence would come from the food and medical product regime, which the dossier does not describe and which is not a narcotics provision.
If prescribed / medical: No narcotics prescription question arises for caffeine, because it is outside Decision No. 158 of 2025 and there is no drug authorisation to obtain. The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule, and caffeine does not depend on that list either. Where a caffeine containing product is a medicine or a supplement, the applicable rules belong to the food and medical product regime, and the dossier does not state them.
Documentation: No drug law documentation applies to caffeine. Provenance: the completed Schedules 1 to 9 non reach search on «الكافيين» was run on 20 September 2026. The only thing worth checking before travelling concerns concentrated or high dose products, which sit with the food and medical product regime rather than with the drug schedules, and the dossier does not record what that regime requires.

United Arab Emirates, Decision No. 158 of 2025, completed Schedules 1 to 9 non reach search for «الكافيين», caffeine, returning no narcotic or psychotropic entry and therefore no Schedule 10 band, with the food and medical product regime governing instead and its terms not recorded in the dossier · the schedules were read at https://sha.shj.ae/#:~:text=%D8%A7%D9%84%D8%AC%D8%AF%D8%A7%D9%88%D9%84%20%D8%A7%D9%84%D9%85%D8%B1%D9%81%D9%82%D8%A9 and the federal instrument at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%83%D8%A7%D9%81%D9%8A%D9%8A%D9%86, the federal legislation portal · the instrument is written in Arabic and the English renderings are the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Caffeine in United Arab Emirates, full detail →

Cannabis / THC

Legal status: Cannabis is carried in two places in Decision No. 158 of 2025, Schedule 1 and Schedule 4, and the printed entry is «القنب؛ راتنج القنب؛ نبات القنب», which names the drug, the resin and the plant as three limbs of one entry. That three limb structure is why this row has a wider article set than most: the dossier attaches Articles 10, 14, 41, 42 and 57, with Article 14 the plant provision, so growing, holding plant material and holding resin are each reached rather than only the finished drug. A cannabis question in the United Arab Emirates therefore does not reduce to a single substance question, and the answer changes with which limb the material falls under. The dossier gives the content of Article 57 and does not state what Articles 10, 14, 41 and 42 provide. Schedule 10 carries the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Article 57 names Schedules 1, 2, Schedule 4 Section I and 5, and cannabis is in both Schedule 1 and Schedule 4, so the row is inside that group twice over. The dossier records the article as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, so the capital route on cannabis is quantity free in the same way it is for the opiate rows, which is the single most counterintuitive fact on this cell. A reader who expects a weight is looking for something the article does not contain, and the Schedule 10 bands, which do exist, are recorded as not gating the Article 57 route. Below the trafficking trigger the dossier attaches Articles 41 and 42 for use and the plant provision at Article 14, without stating any of their tariffs, so no term of years is stated here for possession or cultivation.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule, so no traveller list decides placement. Attached to this substance: cannabis is in Schedule 1 and Schedule 4 at the entry «القنب؛ راتنج القنب؛ نبات القنب», and the dossier records no medical cannabis route, no prescribing pathway and no product exemption at any strength or form. Because the entry names the plant as well as the drug, a preparation, a resin and raw plant material all land inside the placement rather than outside it, which is the point at which foreign medical cannabis documentation most often fails. The permit question itself is not answered by the dossier and is deferred.
Documentation: There is no medical cannabis document recorded in this dossier for the United Arab Emirates, so on this record a foreign prescription, a dispensary label and a physician's letter are all evidence about a substance that remains inside Schedule 1 and Schedule 4. Provenance: the two placements and the entry «القنب؛ راتنج القنب؛ نبات القنب» were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. The practical consequence is that the safest question to resolve before travelling is not how much may be carried but whether anything may be, and that is a question for the health ministry rather than for a carrier or an airport.

United Arab Emirates, Decision No. 158 of 2025, Schedules 1 and 4, printed entry «القنب؛ راتنج القنب؛ نبات القنب» for cannabis, naming the drug, the resin and the plant · Articles 10, 14, 41, 42 and 57 are the routes the dossier attaches, Article 14 reaching the plant, and the Schedule 10 bands do not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%A7%D9%84%D9%82%D9%86%D8%A8 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Cannabis / THC in United Arab Emirates, full detail →

Cathinone

Legal status: Cathinone, the parent alkaloid, is placed in Schedule 5 of Decision No. 158 of 2025, the psychotropic schedule the dossier describes as the Schedule I equivalent branch. The printed entry is «كاثينون», a bare designation with no derivatives or analogues limb attached to it. Schedule 5 also carries a cathinones block at item 3 which enumerates the substituted members individually, and those two facts have to be read together: the parent is controlled by its own entry and the derivatives are controlled by being enumerated, so the parent entry does not sweep in a substituted cathinone the block has not named. That is the structural reason a cathinone question in the United Arab Emirates turns into a question about which cathinone. This row runs through Articles 10, 41 and 57, with the Schedule 10 bands alongside. The placement was read on 20 September 2026.
Consequences if caught: Schedule 5 is one of the four schedule groups Article 57 names, and the «كاثينون» entry is what places this row inside it rather than in the Schedule 6 to 8 branch that carries Article 58. That difference is the whole of the row: Article 57 is recorded as stating mandatory death for its trafficking or promotion trigger, where Article 58 offers death or life imprisonment as alternatives, so the parent alkaloid sits on the harsher of the two routes. The dossier records Article 57 as stating no quantity, and records that the Schedule 10 bands do not gate it, so the exposure attaches to the schedule and not to an amount. Article 41 carries the personal use route for this branch, with its tariff unstated in the dossier.
If prescribed / medical: The country level traveller material the dossier carries is a single record at the modafinil row, where a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: cathinone is in Schedule 5 at the entry «كاثينون», with no medicinal product or prescribing route recorded against it. The dossier gives no permit procedure for the Schedule 5 branch, so the question is deferred rather than answered.
Documentation: No documentation route is recorded for cathinone. Provenance: the Schedule 5 placement and the entry «كاثينون» were read on 20 September 2026, and the capital analysis rests on Article 57 and not on the Schedule 10 bands. The point worth carrying from this row is that the parent entry does not answer a question about a substituted cathinone, so material identified only as a cathinone type stimulant needs its own member checked against the item 3 block before anything is said about it.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, printed entry «كاثينون» for cathinone, the parent alkaloid, with the substituted members enumerated separately in the Schedule 5 cathinones block at item 3 · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%83%D8%A7%D8%AB%D9%8A%D9%86%D9%88%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Cathinone in United Arab Emirates, full detail →

Clonazepam

Legal status: Clonazepam is individually controlled in Schedule 8 of Decision No. 158 of 2025 at the printed entry «كلونازيبام». The dossier's finding is that its Emirati result does not depend on a blanket benzodiazepine rule: the schedule names the substance, so the placement stands on its own entry. Clonazepam is prescribed as an anticonvulsant as well as for anxiety, and the entry does not distinguish between indications, so the placement follows the molecule rather than the reason it was prescribed. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The dossier states the content of Article 58 and does not state what Articles 11 and 43 provide. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and clonazepam is in Schedule 8, so this ordinary prescription medicine is inside a capital trafficking article. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary rather than mandatory, and it records that the article states no quantity. The Schedule 10 bands do not gate that route. On a medicine dispensed in large tablet counts, the absence of a quantity is the fact most likely to be misread, because the natural assumption is that a personal supply is quantitatively distinguishable from a supply offence and the article does not make that distinction. Article 43 carries the personal use route for this branch, with no tariff stated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: clonazepam is named individually in Schedule 8, so a prescription for it describes a substance the schedule reaches by name. No prescribing route, traveller allowance or permit procedure is recorded for that branch, so the question of what documentation suffices at the border is deferred rather than answered.
Documentation: Carry the prescription and the original dispensing packaging naming clonazepam, with a physician's letter if the indication is a seizure disorder and continuity of supply matters, and raise the permit question with the health ministry before travelling because no Emirati procedure is recorded in the dossier. Provenance: the Schedule 8 placement and the entry «كلونازيبام» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative rather than on the Schedule 10 bands.

United Arab Emirates, Decision No. 158 of 2025, Schedule 8, printed entry «كلونازيبام» for clonazepam, individually controlled rather than reached by a benzodiazepine class rule · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 bands do not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%83%D9%84%D9%88%D9%86%D8%A7%D8%B2%D9%8A%D8%A8%D8%A7%D9%85 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Clonazepam in United Arab Emirates, full detail →

Cocaine

Legal status: Cocaine sits in Schedule 1 of Decision No. 158 of 2025, the instrument carrying the current federal drug schedules. The printed entry is «كوكايين», a single Arabic designation the dossier renders as cocaine, with no salts, isomers or preparations limb printed beside it, so the entry reaches what it names and nothing is carried across by family resemblance. Schedule 1 is the narcotics schedule itself, which is why the federal trafficking and personal use provisions reach this row directly rather than through a traveller information inference. The dossier attaches Articles 10, 41 and 57 to this branch and states the content of Article 57 only, so Articles 10 and 41 are named here as the routes it records rather than described. Schedule 10 of the same instrument carries the quantity bands, and the dossier records that those bands do not gate the Article 57 route for a Schedule 1 substance. The placement was read on 20 September 2026.
Consequences if caught: Schedule 1 is one of the four schedule groups Article 57 names, and the «كوكايين» entry is what puts this row inside it. For those groups the dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger, and as stating no quantity for it. It records separately that the Schedule 10 weight bands, which do set quantities elsewhere in the same instrument, do not gate that route. The distinction carries more weight on this row than any figure would: an article attaching death to a schedule is a different thing from one attaching death above a threshold, and only the second can be answered with a number. Below the trafficking trigger the dossier names Article 41 as the personal use route for this branch without stating its tariff, so no term of years is given here. No cocaine quantity appears anywhere in the dossier's capital analysis and none is inferred into it.
If prescribed / medical: The dossier records at one row, modafinil, that a 268 entry ministry travellers list was checked and expressly not used as a schedule, and that is the country level handle it gives: presence on or absence from that list moves nothing into or out of Decision No. 158. Attached to this substance: cocaine is in Schedule 1, the narcotics schedule proper, and Article 10 is the article the dossier names for that branch without saying what it provides. The dossier carries no prescribing route, no import permit procedure and no exemption for cocaine, so the medical carriage question is deferred here rather than answered.
Documentation: No document recorded in this dossier makes carrying cocaine lawful in the United Arab Emirates, so on what the dossier records there is nothing to carry rather than a list of papers that would help. Provenance: the Schedule 1 placement and the printed entry «كوكايين» were read on 20 September 2026, and the capital analysis for this row rests on Article 57 and not on the Schedule 10 weight bands. Anyone travelling with a cocaine containing medicine has a question this dossier does not answer, and it belongs with the health ministry before departure rather than at the border.

United Arab Emirates, Decision No. 158 of 2025, Schedule 1, printed entry «كوكايين» for cocaine, with Articles 10, 41 and 57 the routes the dossier attaches to this branch and Schedule 10 carrying quantity bands that do not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%83%D9%88%D9%83%D8%A7%D9%8A%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the second being the federal legislation portal · the instrument is written in Arabic and the English renderings given in this cell are the dossier's, not a second printed text · read as at 20 September 2026 · Updated September 21, 2026

Cocaine in United Arab Emirates, full detail →

Codeine

Legal status: Codeine is placed in Schedule 2 of Decision No. 158 of 2025 at the printed entry «كودايين». Schedule 2 is the less restrictive of the two narcotic schedules, which is the ordinary expectation for a substance that appears in cough and analgesic preparations across most of the world. The fact that decides this row is that the lighter schedule does not produce a lighter trafficking route: Article 57 names Schedules 1, 2, Schedule 4 Section I and 5 together, so the Schedule 2 placement sits in the same article group as heroin's Schedule 1 placement. The dossier attaches Articles 10, 41 and 57 to the row and states the content of Article 57 only. Schedule 10 carries the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Schedule 2 is one of the four schedule groups Article 57 names, and codeine's «كودايين» entry is in Schedule 2, so this row carries the capital route despite sitting in the softer narcotic schedule. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, and records that the Schedule 10 bands do not gate that route. A reader who has correctly noticed that codeine is treated more lightly than morphine at the scheduling stage will draw the wrong conclusion about the trafficking stage, because the article groups the two schedules rather than distinguishing them. Article 41 carries the personal use route for this branch, with no tariff stated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule, which is the country level handle it gives. Attached to this substance: codeine is in Schedule 2, and that placement reaches an ordinary pharmacy medicine, so the practical exposure here is a traveller carrying a codeine containing analgesic or cough preparation rather than a trafficking scenario. The dossier records no prescribing route, no strength based exemption and no permit procedure for it, so what a foreign prescription achieves at the border is exactly the question the dossier does not answer, and it is deferred rather than guessed.
Documentation: Carry the prescription and the original dispensing packaging for any codeine containing medicine, and expect the schedule and not the packaging to govern. The dossier records no Emirati permit procedure for this substance, so on this record those documents are evidence about a medicine that remains in Schedule 2 rather than an authorisation that removes it. Provenance: the Schedule 2 placement and the entry «كودايين» were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. The question of whether an advance approval exists belongs with the health ministry before departure.

United Arab Emirates, Decision No. 158 of 2025, Schedule 2, printed entry «كودايين» for codeine, a Schedule 2 narcotic that Article 57 nevertheless groups with Schedules 1, 4 Section I and 5 · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%83%D9%88%D8%AF%D8%A7%D9%8A%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Codeine in United Arab Emirates, full detail →

Crack Cocaine

Legal status: Crack has no separate compound entry in Decision No. 158 of 2025. The dossier resolves the row through the cocaine entry, recording it as «كوكايين؛ كراك كوكايين», on the basis that crack is cocaine in base form rather than a distinct scheduled substance, so the Schedule 1 cocaine entry supplies the controlling regime. That is a chemistry point with a legal consequence: because there is no separate entry, there is also no separate and harsher treatment of the base form, and the analysis for this row is the cocaine analysis without modification. The row therefore runs through Articles 10, 41 and 57, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: The capital route reaches this row through Schedule 1, which is one of the four schedule groups Article 57 names, because the form is cocaine and cocaine is in Schedule 1. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, so nothing turns on weight and nothing turns on the form being smokeable rather than powdered. It records separately that the Schedule 10 bands do not gate the Article 57 route. Any distinction drawn elsewhere in the world between powder and base sentencing has no counterpart here on this record, because the schedule has only one entry for both. Article 41 carries the personal use route for this branch, its tariff unstated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: crack has no entry of its own and is reached through the Schedule 1 cocaine entry, so there is no separate entry for a prescription to attach to even in principle. No prescribing route, exemption or permit is recorded, and the medical question is deferred rather than answered.
Documentation: There is no document recorded that would make carriage of cocaine in base form lawful, and nothing in the dossier treats it differently from cocaine for that purpose. Provenance: the entry relied on is «كوكايين؛ كراك كوكايين» at Schedule 1, read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. The single point worth carrying is that the absence of a crack entry is not a gap in the scheduling, it is the reason the cocaine entry governs.

United Arab Emirates, Decision No. 158 of 2025, no separate crack entry · the row is controlled through cocaine at Schedule 1, printed entry «كوكايين؛ كراك كوكايين», crack being cocaine in base form · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%83%D9%88%D9%83%D8%A7%D9%8A%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Crack Cocaine in United Arab Emirates, full detail →

Delta-8-THC

Legal status: Delta-8-THC is reached through the tetrahydrocannabinol and isomer entry in Schedule 5 of Decision No. 158 of 2025, at the printed entry «دلتا-8-تتراهيدروكانابينول». The entry names the delta-8 isomer specifically rather than leaving it to the general cannabinoid heading, which is the fact that settles this row: the hemp derived argument used for delta-8 in other jurisdictions runs on the isomer being outside a definition written around delta-9, and here the isomer is printed in its own right. The dossier's cannabinoid searches on other rows found that the schedule enumerates specified tetrahydrocannabinol variants together with dronabinol, nabilone and hexahydrocannabinol, which is consistent with an enumerated rather than a generic approach. The row runs through Articles 10, 41 and 57, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Schedule 5 is one of the four schedule groups Article 57 names, and the delta-8 entry places this row inside it, so a product sold as a legal hemp cannabinoid elsewhere carries the capital route here. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as naming no quantity, and records that the Schedule 10 bands do not gate that route. The gap between the commercial framing of delta-8 and its position in this schedule is the whole risk on the row, and it is not narrowed by the product being low potency, openly sold in the country of purchase, or labelled as hemp derived. Article 41 carries the personal use route for this branch, with no tariff stated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule, so no traveller list decides placement here. Attached to this substance: delta-8-THC is reached by the Schedule 5 tetrahydrocannabinol and isomer entry, and the dossier records no medicinal delta-8 product, prescribing route or permit. Whether a cannabinoid medicine of any kind can be authorised is not answered in the dossier and is deferred rather than inferred from the presence of dronabinol and nabilone in the schedule.
Documentation: No documentation route is recorded for delta-8-THC, and a purchase receipt or a certificate of analysis from a jurisdiction where the product is sold openly is not an Emirati authorisation. Provenance: the entry «دلتا-8-تتراهيدروكانابينول» and the Schedule 5 isomer route were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. The practical point is that this row is decided by the isomer being named in the schedule, so a label describing the product as hemp derived does not engage any exception recorded here.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5 tetrahydrocannabinol and isomer entry, printed entry «دلتا-8-تتراهيدروكانابينول» for delta-8-THC, the isomer being named rather than left to a generic heading · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%AF%D9%84%D8%AA%D8%A7-8-%D8%AA%D8%AA%D8%B1%D8%A7%D9%87%D9%8A%D8%AF%D8%B1%D9%88%D9%83%D8%A7%D9%86%D8%A7%D8%A8%D9%8A%D9%86%D9%88%D9%84 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Delta-8-THC in United Arab Emirates, full detail →

Diazepam

Legal status: Diazepam is a Schedule 8 psychotropic under Decision No. 158 of 2025, at the printed entry «ديازيبام». The dossier's finding is that unauthorised personal use remains punishable even though therapeutic prescribing is permitted, which is the two part structure worth stating: the permission and the offence coexist rather than one displacing the other, and what decides a given case is the authorisation behind the tablets and not the fact that the substance is prescribable at all. The entry names diazepam and not the class, and the other five benzodiazepines in this table are named separately in the same schedule. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and diazepam is in Schedule 8, so the most familiar benzodiazepine in the table sits inside a capital trafficking article. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary and not mandatory on this row, and it records that the article states no quantity. The Schedule 10 bands do not gate that route. Beneath the trafficking trigger the dossier separately records that unauthorised personal use is punishable, with Article 43 the route and its tariff unstated, so the row has a real non capital exposure as well as the capital one and neither should be reported without the other.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: diazepam is individually named in Schedule 8, and the dossier records that therapeutic prescribing is permitted while unauthorised use is not. What it does not record is the procedure by which a traveller's own prescription becomes an Emirati authorisation, so that step is deferred here rather than assumed from the fact that prescribing exists.
Documentation: Carry the prescription and the original dispensing packaging naming diazepam, and keep the tablets in the labelled container rather than loose, because the label is what connects the medicine to the prescription. The dossier records therapeutic prescribing as permitted without recording a traveller procedure, so the permit question belongs with the health ministry before departure. Provenance: the Schedule 8 placement and the entry «ديازيبام» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative.

United Arab Emirates, Decision No. 158 of 2025, Schedule 8, printed entry «ديازيبام» for diazepam, individually named alongside the other five benzodiazepine members in this table · the dossier records therapeutic prescribing as permitted while unauthorised personal use remains punishable · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 bands do not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%AF%D9%8A%D8%A7%D8%B2%D9%8A%D8%A8%D8%A7%D9%85 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Diazepam in United Arab Emirates, full detail →

DMT

Legal status: Dimethyltryptamine is placed in Schedule 5 of Decision No. 158 of 2025 at the printed entry «ثنائي ميثيل تريبتامين؛ DMT», which gives the Arabic chemical name and the abbreviation in the same entry. Schedule 5 is the first psychotropic schedule in this instrument, and the placement is the compound's own rather than a plant or preparation limb, so it reaches the substance wherever it is found and whatever it was extracted from. That is why the dossier resolves the ayahuasca row through this entry instead of through any brew specific provision. The row runs through Articles 10, 41 and 57, with Schedule 10 carrying the quantity bands. The dossier states the content of Article 57 and not of Articles 10 and 41. The placement was read on 20 September 2026.
Consequences if caught: Schedule 5 is one of the four schedule groups Article 57 names, and the «ثنائي ميثيل تريبتامين؛ DMT» entry places this row inside it. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, so the capital route attaches to the substance and the conduct without any weight having to be established. It records separately that the Schedule 10 bands, which do set quantities elsewhere in the instrument, do not gate that route. Because this entry also governs any preparation proved to contain the compound, the exposure follows the chemistry into brews, extracts and infusions rather than stopping at the crystalline form. Article 41 carries the personal use route for this branch, with its tariff unstated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: dimethyltryptamine is in Schedule 5 at its own compound entry, and no medicinal product, prescribing route or permit is recorded against it. The dossier carries no research or ceremonial authorisation for the Schedule 5 branch, so the question of any lawful route is deferred rather than answered.
Documentation: No documentation route is recorded for dimethyltryptamine. Provenance: the Schedule 5 placement and the entry «ثنائي ميثيل تريبتامين؛ DMT» were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. The point worth carrying is that the entry is the compound's, so a preparation described by a plant or ritual name is documented by what it contains rather than by what it is called.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, printed entry «ثنائي ميثيل تريبتامين؛ DMT» for dimethyltryptamine, a compound entry that also supplies the route for preparations proved to contain it · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%AB%D9%86%D8%A7%D8%A6%D9%8A%20%D9%85%D9%8A%D8%AB%D9%8A%D9%84%20%D8%AA%D8%B1%D9%8A%D8%A8%D8%AA%D8%A7%D9%85%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

DMT in United Arab Emirates, full detail →

DOM

Legal status: The substance known as DOM is placed in Schedule 5 of Decision No. 158 of 2025 at the printed entry «DOM؛ STP؛ 2،5-ثنائي ميثوكسي-4-ميثيل أمفيتامين». The entry carries three designations at once, the abbreviation, the older street name and the Arabic chemical description of the 2,5-dimethoxy-4-methyl amphetamine, so the placement does not depend on which of the names a report happens to use. Schedule 5 is the most restrictive psychotropic schedule used by this instrument, which is what puts the row in the Article 57 group rather than the Schedule 6 to 8 group carrying Article 58. The row runs through Articles 10, 41 and 57, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Schedule 5 is one of the four schedule groups Article 57 names, and this entry is in Schedule 5, so the harsher of the two trafficking articles reaches the row. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and Article 58, which governs the other schedule group, as offering death or life imprisonment as alternatives; this substance is on the mandatory side. Article 57 states no quantity, and the dossier records that the Schedule 10 bands do not gate it, so there is no weight at which the route opens or closes. Article 41 carries the personal use route for this branch, with no tariff stated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: the Schedule 5 placement at the three name entry, with no medicinal product, prescribing route or permit recorded against it anywhere in the dossier. The medical question is deferred rather than reasoned out of the Schedule 5 branch.
Documentation: No documentation route is recorded for this substance. Provenance: the entry «DOM؛ STP؛ 2،5-ثنائي ميثوكسي-4-ميثيل أمفيتامين» and its Schedule 5 placement were read on 20 September 2026, and the capital analysis rests on Article 57 rather than on the Schedule 10 bands. Because the entry prints three names for one substance, a report using any of them is describing the same placement and none of the three is a safer description than the others.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, printed entry «DOM؛ STP؛ 2،5-ثنائي ميثوكسي-4-ميثيل أمفيتامين», carrying the abbreviation, the street name and the Arabic chemical description · Articles 10, 41 and 57 attach to this branch, Article 57 being the mandatory death route where Article 58 is the death or life alternative, and the Schedule 10 bands do not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=DOM and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

DOM in United Arab Emirates, full detail →

Etizolam

Legal status: Etizolam is placed in Schedule 8 of Decision No. 158 of 2025 at the printed entry «إيتزولام». The dossier's finding is that it is treated in the Schedule 8 branch rather than as an unscheduled analogue, and that matters more here than on the other five benzodiazepine rows in this table: etizolam is a thienodiazepine rather than a true benzodiazepine, so in a country that controlled the class by description it would be the member most likely to fall outside. This instrument names it, which removes the argument entirely. The placement therefore rests on the entry and not on whether the compound answers to the class word. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and etizolam is in Schedule 8, so the article applies to the row. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary rather than mandatory, and it records that the article states no quantity. The Schedule 10 bands do not gate that route. Etizolam reaches buyers through channels that present it as a research chemical or an unregulated alternative, and the schedule entry is the answer to that framing: being named is what puts it inside Article 58, and how it was sold does not bear on that. Article 43 carries the personal use route, with its tariff unstated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: etizolam is named individually in Schedule 8. It is a licensed medicine in some countries and not in others, and the dossier records no prescribing route, traveller allowance or permit procedure for the Emirati placement, so a prescription issued where it is licensed has an effect at this border that the dossier does not state. The question is deferred rather than answered.
Documentation: If the medicine was lawfully prescribed elsewhere, carry the prescription and the original dispensing packaging naming etizolam, and expect the schedule entry rather than the foreign licence to govern. Provenance: the Schedule 8 placement and the entry «إيتزولام» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative rather than on the Schedule 10 bands. Material bought online as a research chemical has no documentation that would help here, because the entry names the substance whatever the packaging calls it.

United Arab Emirates, Decision No. 158 of 2025, Schedule 8, printed entry «إيتزولام» for etizolam, a thienodiazepine named individually rather than left to a benzodiazepine class description · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 bands do not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%A5%D9%8A%D8%AA%D8%B2%D9%88%D9%84%D8%A7%D9%85 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Etizolam in United Arab Emirates, full detail →

Fentanyl

Legal status: Fentanyl is placed in Schedule 1 of Decision No. 158 of 2025 at the printed entry «فنتانيل». Schedule 1 is the narcotics schedule proper, so a substance with an established hospital anaesthetic and analgesic role is carried at the top of the narcotic scheduling rather than in a medicines tier, and the dossier is explicit that the Schedule 1 penalty architecture governs rather than ordinary prescription drug penalties. The entry is a bare designation with no analogues limb printed beside it, which matters for a compound family whose illicit forms are usually analogues: this entry names fentanyl and a proved analogue would need its own placement. The row runs through Articles 10, 41 and 57, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Schedule 1 is one of the four schedule groups Article 57 names, and the «فنتانيل» entry is in Schedule 1. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, which on a substance dosed in micrograms removes the one variable a reader would expect to matter most. It records separately that the Schedule 10 bands do not gate the Article 57 route, so the potency of the material and the smallness of a viable quantity change nothing about whether the capital route is available. Article 41 carries the personal use route for this branch, with no tariff stated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: fentanyl is in Schedule 1, and its recognised clinical use does not appear in the dossier as a scheduling carve out, so a patch, a lozenge or an injectable preparation is inside the same placement as the powder. No prescribing route, strength based exemption or permit procedure is recorded, so the question of what documentation a patient would need is deferred rather than answered.
Documentation: Carry the prescription, the original dispensing packaging and a physician's letter for any fentanyl containing medicine, and treat them as evidence about the medicine rather than as an authorisation, because no Emirati permit procedure is recorded in this dossier. Provenance: the Schedule 1 placement and the entry «فنتانيل» were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. Because the entry names fentanyl and not its analogues, material described only as a fentanyl type opioid is a separate question that this row does not answer.

United Arab Emirates, Decision No. 158 of 2025, Schedule 1, printed entry «فنتانيل» for fentanyl, a bare designation with no analogues limb · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%81%D9%86%D8%AA%D8%A7%D9%86%D9%8A%D9%84 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Fentanyl in United Arab Emirates, full detail →

Gabapentin

Legal status: Gabapentin appears twice in Decision No. 158 of 2025. It is placed at Schedule 8, item 38, at the printed entry «جابابنتين» with the chemical name the dossier renders as 2-[1-(aminomethyl)cyclohexyl]acetic acid, and it appears again at Schedule 9, item 19, where the schedule prints a 3,600 mg figure against it. The two entries do different work: Schedule 8 is the placement that carries the penalty articles, and Schedule 9 is where the instrument records quantities for controlled medicines. Reading only the Schedule 9 figure would produce the impression of a permitted amount with no schedule behind it, and reading only Schedule 8 would miss that the instrument states a quantity for this substance at all. The row runs through Articles 11, 43 and 58, with Schedule 10 group 3 carrying the penal quantity band. The placements were read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and gabapentin's controlling placement is Schedule 8, item 38, so the article applies to the row. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary rather than mandatory, and it records that the article states no quantity. Neither of the two figures attached to this substance is a capital threshold: the Schedule 9 figure of 3,600 mg is a medicines control quantity, and the Schedule 10 group 3 band does not gate Article 58. That is three separate numbers and articles to keep apart on one row, and conflating any two of them produces a threshold that does not exist. Article 43 carries the personal use route, with its tariff unstated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: gabapentin is at Schedule 8, item 38, and Schedule 9, item 19 prints 3,600 mg against it. That Schedule 9 figure is the nearest thing to a medicines rule the dossier carries for this row, and the dossier does not state what procedure attaches to it, whether it is a daily limit, a dispensing limit or a carriage limit, so it is reported here as a printed quantity rather than interpreted. The permit question itself is deferred.
Documentation: Carry the prescription and the original dispensing packaging naming gabapentin, and note the daily dose, because the instrument prints a 3,600 mg figure against this substance at Schedule 9, item 19 and the dossier does not state what that figure governs. Provenance: the Schedule 8, item 38 placement, the Schedule 9, item 19 figure and the entry «جابابنتين» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative. Put the question of what the 3,600 mg figure permits to the health ministry rather than assuming it is a traveller allowance.

United Arab Emirates, Decision No. 158 of 2025, Schedule 8, item 38, printed entry «جابابنتين» for gabapentin with the chemical name rendered as 2-[1-(aminomethyl)cyclohexyl]acetic acid, and separately Schedule 9, item 19, which prints 3,600 mg against it · Articles 11, 43 and 58 attach to the Schedule 8 placement, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and neither the Schedule 9 figure nor the Schedule 10 group 3 band is a capital threshold · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%AC%D8%A7%D8%A8%D8%A7%D8%A8%D9%86%D8%AA%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English renderings are the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Gabapentin in United Arab Emirates, full detail →

GBL

Legal status: Gamma-butyrolactone is expressly listed at Schedule 8, item 39 of Decision No. 158 of 2025, at the printed entry «جي بي إل؛ غاما-بوتيرولاكتون», with the dossier rendering the chemical name as dihydrofuran-2(3H)-one. The express listing is the finding: this compound is an industrial solvent as well as a precursor that converts in the body to the substance carried in Schedule 6, and in a country that controlled only the end product it would be argued about. Here it is named, so its status does not depend on the conversion argument. Note the split that follows: the lactone is Schedule 8 and the hydroxybutyrate is Schedule 6, two different schedules within the same Article 58 group. The row runs through Articles 11, 43 and 58, with Schedule 10 group 3 carrying the quantity band. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and this compound is at Schedule 8, item 39, so the article applies. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary rather than mandatory, and it records that the article states no quantity. The Schedule 10 group 3 band does not gate that route. Because the substance has genuine industrial uses, the conduct rather than the possession is where the article bites, and there is no volume at which the trafficking or promotion trigger becomes unavailable. Article 43 carries the personal use route for this branch, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: the placement at Schedule 8, item 39, with no medicinal product behind it, since this compound is a solvent and a precursor rather than a medicine. No prescribing route or permit procedure is recorded, and the dossier does not describe any industrial licensing route either, so both questions are deferred rather than answered.
Documentation: No medical documentation route is recorded for this substance, and the dossier describes no industrial or commercial licence for it either. Provenance: the entry «جي بي إل؛ غاما-بوتيرولاكتون» at Schedule 8, item 39 was read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative rather than on the Schedule 10 group 3 band. The point worth carrying is that a container labelled as a cleaning or industrial product contains a named scheduled substance, and the label does not change the entry.

United Arab Emirates, Decision No. 158 of 2025, Schedule 8, item 39, printed entry «جي بي إل؛ غاما-بوتيرولاكتون», the dossier rendering the chemical name as dihydrofuran-2(3H)-one, expressly listed rather than reached as a precursor to the Schedule 6 hydroxybutyrate · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 group 3 band does not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%AC%D9%8A%20%D8%A8%D9%8A%20%D8%A5%D9%84 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

GBL in United Arab Emirates, full detail →

GHB

Legal status: Gamma-hydroxybutyrate is controlled in Schedule 6 of Decision No. 158 of 2025, the psychotropic Schedule II equivalent branch, at the printed entry «حمض غاما-هيدروكسي بيوتيريك؛ GHB», which prints the acid name in Arabic alongside the abbreviation. The dossier's finding is that this Schedule 6 placement is what gives the row Article 58's trafficking consequence rather than Article 57's mandatory death wording. Read against the lactone row in this table, which is at Schedule 8, item 39, the pair shows the instrument placing a substance and its precursor in different schedules that nonetheless fall inside the same article. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and this substance is in Schedule 6, so the article applies to the row. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, which makes death discretionary rather than mandatory, and records that the article states no quantity. The Schedule 10 bands do not gate that route. Because the substance is handled as a liquid in small doses, a volume based intuition is especially tempting here, and the article supplies nothing to support it: the route attaches to the schedule and the conduct. Article 43 carries the personal use route for this branch, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: the Schedule 6 placement at «حمض غاما-هيدروكسي بيوتيريك؛ GHB». The substance has a licensed medical use for narcolepsy in some health systems, and the dossier records no corresponding Emirati prescribing route, traveller allowance or permit procedure, so a patient prescribed it elsewhere has a question the dossier does not answer and it is deferred here.
Documentation: If the substance was lawfully prescribed elsewhere, carry the prescription, the original dispensing packaging and a letter from the prescribing service, and settle the permit question with the health ministry before travelling, because no Emirati procedure is recorded in the dossier. Provenance: the Schedule 6 placement and the entry «حمض غاما-هيدروكسي بيوتيريك؛ GHB» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative rather than on the Schedule 10 bands.

United Arab Emirates, Decision No. 158 of 2025, Schedule 6 (psychotropic Schedule II equivalent), printed entry «حمض غاما-هيدروكسي بيوتيريك؛ GHB», the precursor lactone being placed separately at Schedule 8, item 39 within the same article group · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 bands do not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%AD%D9%85%D8%B6%20%D8%BA%D8%A7%D9%85%D8%A7-%D9%87%D9%8A%D8%AF%D8%B1%D9%88%D9%83%D8%B3%D9%8A%20%D8%A8%D9%8A%D9%88%D8%AA%D9%8A%D8%B1%D9%8A%D9%83 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

GHB in United Arab Emirates, full detail →

Heroin

Legal status: Heroin is placed in Schedule 1 of Decision No. 158 of 2025 at the printed entry «هيروين؛ ثنائي أسيتيل مورفين», which carries the common name and the diacetylmorphine chemical name in the same entry. Printing both closes the gap that a laboratory certificate naming only the chemical form would otherwise open, since the schedule reaches the substance under either description. Schedule 1 is the narcotics schedule itself, so the federal handling, personal use and trafficking provisions apply directly to the row. The dossier attaches Articles 10, 41 and 57 and states the content of Article 57 only. Schedule 10 carries the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Schedule 1 is one of the four schedule groups Article 57 names, and heroin's entry is in Schedule 1. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, so the capital route on the substance most readers already associate with the severest treatment is nonetheless not a threshold route. It records separately that the Schedule 10 bands do not gate that route, which means the weight bands that do exist in the instrument answer a different question. The reason to be precise about this rather than to report the outcome loosely is that a threshold rule can be reasoned about with a number and a schedule rule cannot, and only one of those two is what this article contains. Article 41 carries the personal use route for this branch, its tariff unstated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: heroin is in Schedule 1 under both the common and the diacetylmorphine name, and the dossier records no medicinal preparation, prescribing route or permit for it in the United Arab Emirates. Diamorphine is prescribed in some health systems, and nothing in this dossier extends that to the Emirati placement, so the question is deferred rather than answered by analogy.
Documentation: No document recorded in this dossier makes carriage of heroin or of a diacetylmorphine preparation lawful, so on this record there is nothing to carry. Provenance: the Schedule 1 placement and the entry «هيروين؛ ثنائي أسيتيل مورفين» were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. A traveller prescribed diamorphine in another health system has a question the dossier does not answer, and it belongs with the health ministry before departure.

United Arab Emirates, Decision No. 158 of 2025, Schedule 1, printed entry «هيروين؛ ثنائي أسيتيل مورفين» for heroin, carrying both the common name and the diacetylmorphine chemical name · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%87%D9%8A%D8%B1%D9%88%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Heroin in United Arab Emirates, full detail →

HHC

Legal status: Hexahydrocannabinol is in Schedule 1 of Decision No. 158 of 2025 as a current national addition made in the 2025 republication of the schedules, at the printed entry «هكساهيدروكانابينول؛ HHC». The dossier treats the 2025 republication as the fact that closes this row: the compound is named expressly in both the Arabic and the abbreviated form, so it does not depend on being read into a tetrahydrocannabinol entry. Its placement in Schedule 1 rather than in the psychotropic schedules is notable, because the same instrument carries the specified tetrahydrocannabinol variants in Schedule 5, and the dossier's cannabinoid searches on other rows record hexahydrocannabinol as present while cannabidiol and cannabinol are not. The row runs through Articles 10, 41 and 57, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Schedule 1 is one of the four schedule groups Article 57 names, and the hexahydrocannabinol entry is a Schedule 1 entry, so a cannabinoid marketed in several countries as a lawful alternative to tetrahydrocannabinol sits in the narcotics schedule here. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity, and records that the Schedule 10 bands do not gate that route. The distance between how this compound is sold and where it is scheduled is the whole of the risk, and the recency of the addition makes it worse rather than better, because a traveller's information about it is likely to predate the 2025 republication. Article 41 carries the personal use route for this branch, with its tariff unstated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: hexahydrocannabinol is in Schedule 1 as a 2025 national addition, and the dossier records no medicinal product, prescribing route or permit against that entry. Dronabinol and nabilone appear in the dossier's cannabinoid searches as separately named substances, which is not a route for this compound, so the medical question here is deferred rather than borrowed.
Documentation: No documentation route is recorded for hexahydrocannabinol, and a vendor's compliance statement from a jurisdiction where it is sold is not an Emirati authorisation. Provenance: the entry «هكساهيدروكانابينول؛ HHC» and its Schedule 1 placement as a current 2025 national addition were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. The practical point is that the addition is recent, so any guidance about this compound that predates the 2025 republication should be treated as out of date rather than as a second opinion.

United Arab Emirates, Decision No. 158 of 2025, Schedule 1, printed entry «هكساهيدروكانابينول؛ HHC» for hexahydrocannabinol, a current national addition in the 2025 republication of the schedules · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%87%D9%83%D8%B3%D8%A7%D9%87%D9%8A%D8%AF%D8%B1%D9%88%D9%83%D8%A7%D9%86%D8%A7%D8%A8%D9%8A%D9%86%D9%88%D9%84 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

HHC in United Arab Emirates, full detail →

Hydrocodone

Legal status: Hydrocodone is placed in Schedule 1 of Decision No. 158 of 2025 at the printed entry «هيدروكودون». The dossier's point about this row is that medical use does not move the placement: hydrocodone is a widely prescribed oral opioid and it is nonetheless in the narcotics schedule proper, so lawful prescribing elsewhere does not erase the schedule based criminal route for unauthorised conduct here. The entry names the substance alone, with no combination product limb, which matters because hydrocodone is usually dispensed in fixed combinations, and the placement follows the controlled component rather than the product name on the box. The row runs through Articles 10, 41 and 57, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Schedule 1 is one of the four schedule groups Article 57 names, and hydrocodone's entry is in Schedule 1, so the capital route reaches a prescription opioid on the same footing as an illicit one. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity, and records that the Schedule 10 bands do not gate that route. What separates lawful from unlawful on this row is therefore the authorisation and the conduct, not the number of tablets, and a quantity based intuition imported from a domestic prescribing rule will not describe the exposure correctly. Article 41 carries the personal use route for this branch, with no tariff stated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: hydrocodone is in Schedule 1 and the entry names the opioid rather than any combination product, so a cough or analgesic preparation containing it is inside the placement regardless of what the product is called. The dossier records no prescribing route, no import permit procedure and no quantity allowance for travellers, so the question of what a patient may bring is deferred rather than answered.
Documentation: Carry the prescription and the original dispensing packaging showing the active ingredient rather than only the brand, because the placement attaches to hydrocodone and a brand name does not disclose it. On this record those documents are evidence about a medicine that is in Schedule 1, and no Emirati permit procedure is described in the dossier that would convert them into an authorisation. Provenance: the Schedule 1 placement and the entry «هيدروكودون» were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands.

United Arab Emirates, Decision No. 158 of 2025, Schedule 1, printed entry «هيدروكودون» for hydrocodone, the entry naming the opioid and not any combination product · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%87%D9%8A%D8%AF%D8%B1%D9%88%D9%83%D9%88%D8%AF%D9%88%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Hydrocodone in United Arab Emirates, full detail →

Ketamine

Legal status: Ketamine is placed at Schedule 6, item 7 of Decision No. 158 of 2025, at the printed entry «كيتامين؛ كيتالار», which carries the substance name and the Ketalar trade name together, with the chemical name the dossier renders as 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone. Printing the trade name is unusual and useful: it means a product identified only by that brand is reached by the entry without having to establish the generic name first. The same schedule carries the fluoro analogue four items earlier at item 3, so the instrument is enumerating the arylcyclohexylamines individually rather than by description. The row runs through Articles 11, 43 and 58, with Schedule 10 group 3 carrying the quantity band. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and ketamine is at Schedule 6, item 7, so the article applies to a substance that is also a hospital anaesthetic on the essential medicines lists of most health systems. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary rather than mandatory, and it records that the article states no quantity. The Schedule 10 group 3 band does not gate that route. The gap between the clinical standing of the drug and the severity of the article is the finding here, and it is not narrowed by the material being of pharmaceutical origin. Article 43 carries the personal use route, with its tariff unstated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: ketamine is at Schedule 6, item 7, and the entry expressly includes the Ketalar trade name, so a product carried under that brand is inside the placement. The dossier records no prescribing route, clinical exemption or permit procedure for the branch, so the question of how a lawful clinical supply is authorised is deferred rather than answered.
Documentation: If the substance is carried as a prescribed medicine, carry the prescription and the original dispensing packaging showing the active ingredient, and note that the schedule names the Ketalar brand explicitly so the brand does not put the product outside the entry. Provenance: the Schedule 6, item 7 placement and the entry «كيتامين؛ كيتالار» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative rather than on the Schedule 10 group 3 band. The permit question belongs with the health ministry before departure.

United Arab Emirates, Decision No. 158 of 2025, Schedule 6, item 7, printed entry «كيتامين؛ كيتالار» for ketamine, the entry carrying the Ketalar trade name and the chemical name rendered as 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone, with the fluoro analogue enumerated separately at item 3 · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 group 3 band does not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%83%D9%8A%D8%AA%D8%A7%D9%85%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English renderings are the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Ketamine in United Arab Emirates, full detail →

Khat

Legal status: Khat is placed at Schedule 4, Section I, item 5 of Decision No. 158 of 2025, the entry being «القات؛ أوراق Catha edulis», the leaves of Catha edulis. The dossier records that a current Cabinet measure expressly cross references the leaves as clause 5 of Section I of Schedule 4, and draws the conclusion that matters: khat is a named scheduled entry and not merely an unscheduled intoxicating plant reached by a general conduct rule. That distinction separates this row from the amanita, amyl nitrite and nitrous oxide rows in the same country, which have no schedule entry and are reached, if at all, through the conduct based provisions. The dossier attaches Articles 10 and 57 to this row, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Article 57 names Schedules 1, 2, Schedule 4 Section I and 5, and khat's entry is at Schedule 4, Section I, item 5, so the leaves are inside the article's Section I limb by name. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, and records that the Schedule 10 bands do not gate that route. Section I is doing real work here: the article does not reach all of Schedule 4, it reaches Section I of it, and the entry's position at item 5 of that section is what puts the row inside the capital group. A quantity of leaves carried for chewing is therefore not a different legal category from a consignment on this article, because the article contains no quantity at all. Article 10 is the third route the dossier attaches and its content is not stated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: khat is at Schedule 4, Section I, item 5 as the leaves of the plant, so there is no medicinal product behind the entry for a prescription to attach to. The dossier records no cultural, dietary or personal use allowance, and none is inferred here, so the question of any lawful route is deferred.
Documentation: No documentation route is recorded for khat, and lawful purchase or customary use in the country of departure is not an Emirati authorisation. Provenance: the placement at Schedule 4, Section I, item 5 and the entry «القات؛ أوراق Catha edulis» were read on 20 September 2026, with the capital analysis resting on Article 57's Section I limb and not on the Schedule 10 bands. The practical point is that the entry names leaves, so fresh plant material in baggage is the exact thing the entry describes rather than a borderline case.

United Arab Emirates, Decision No. 158 of 2025, Schedule 4, Section I, item 5, printed entry «القات؛ أوراق Catha edulis» for khat, the dossier recording a current Cabinet measure cross referencing the leaves as clause 5 of Section I · Article 57 reaches Section I of Schedule 4 by name and states no quantity, Article 10 is the other route attached, and the Schedule 10 bands do not gate Article 57 · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%A7%D9%84%D9%82%D8%A7%D8%AA and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Khat in United Arab Emirates, full detail →

Lorazepam

Legal status: Lorazepam is individually listed in Schedule 8 of Decision No. 158 of 2025 at the printed entry «لورازيبام». The dossier's finding is precise and it is worth keeping: the individual listing leaves no basis to use another benzodiazepine's schedule by analogy. That cuts both ways, because it is also the reason a member the schedule does not name cannot be placed by pointing at this one. Lorazepam is used in acute settings as well as for anxiety, and the entry does not distinguish by indication or by route of administration. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and lorazepam is in Schedule 8, so the article applies to the row. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary here and not mandatory, and it records that the article states no quantity. The Schedule 10 bands do not gate that route. Because Schedule 8 is the lowest of the psychotropic schedules in the instrument, this row is a clean demonstration that a low placement does not mean a low ceiling: the schedule determines which article applies and not how severe that article is. Article 43 carries the personal use route, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: lorazepam is named individually in Schedule 8, so a prescription for it evidences a substance the schedule reaches by name rather than by class. No prescribing route, traveller allowance or permit procedure is recorded for that branch, so the border question is deferred rather than answered.
Documentation: Carry the prescription and the original dispensing packaging naming lorazepam, and keep them with the medicine rather than in checked baggage separated from it. The dossier records no Emirati permit procedure, so those documents are evidence about the medicine rather than an authorisation, and the permit question belongs with the health ministry before departure. Provenance: the Schedule 8 placement and the entry «لورازيبام» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative.

United Arab Emirates, Decision No. 158 of 2025, Schedule 8, printed entry «لورازيبام» for lorazepam, individually listed so that no other benzodiazepine's schedule is available by analogy in either direction · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 bands do not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%84%D9%88%D8%B1%D8%A7%D8%B2%D9%8A%D8%A8%D8%A7%D9%85 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Lorazepam in United Arab Emirates, full detail →

LSD

Legal status: Lysergide is placed in Schedule 5 of Decision No. 158 of 2025 at the printed entry «ثنائي إيثيل أميد حمض الليسرجيك؛ LSD», which prints the Arabic form of lysergic acid diethylamide together with the abbreviation. The entry is the diethylamide specifically, and the dossier's searches on two neighbouring rows confirm how narrowly that reads: the amide form and the propionyl analogue were both searched against this schedule and neither was found, while this entry was. Schedule 5 is the first psychotropic schedule in the instrument, which puts the row in the Article 57 group rather than the Schedule 6 to 8 group that carries Article 58. The row runs through Articles 10, 41 and 57, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Schedule 5 is one of the four schedule groups Article 57 names, and the lysergide entry is in Schedule 5. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, so on a substance dosed in micrograms and carried on paper there is no weight at which the capital route becomes available or ceases to be. It records separately that the Schedule 10 bands do not gate that route. The absence of a quantity is the single most important thing on this cell, because the physical form invites a quantity based intuition that the article does not support. Article 41 carries the personal use route for this branch, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: lysergide is in Schedule 5 at its own entry, with no medicinal product, research authorisation or prescribing route recorded against it. No permit procedure appears anywhere in the dossier for this branch, so the question is deferred rather than answered.
Documentation: No documentation route is recorded for lysergide. Provenance: the Schedule 5 placement and the entry «ثنائي إيثيل أميد حمض الليسرجيك؛ LSD» were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. The point worth carrying is that the entry names the diethylamide, so a substance identified only as a lysergamide is a separate question, and the dossier records that two such compounds were searched for in this schedule without being found.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, printed entry «ثنائي إيثيل أميد حمض الليسرجيك؛ LSD» for lysergide, the entry naming the diethylamide · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%AB%D9%86%D8%A7%D8%A6%D9%8A%20%D8%A5%D9%8A%D8%AB%D9%8A%D9%84%20%D8%A3%D9%85%D9%8A%D8%AF%20%D8%AD%D9%85%D8%B6%20%D8%A7%D9%84%D9%84%D9%8A%D8%B3%D8%B1%D8%AC%D9%8A%D9%83 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

LSD in United Arab Emirates, full detail →

MDA

Legal status: Tenamfetamine is placed in Schedule 5 of Decision No. 158 of 2025 at the printed entry «MDA؛ ميثيلين ديوكسي أمفيتامين», which carries the abbreviation and the Arabic methylenedioxy amphetamine description. The dossier's finding on this row is that the substance is controlled by its own entry and is not interchangeable with the N-methylated compound that has an entry of its own in the same schedule, so sharing the substituted amphetamine skeleton is not the reason either is controlled. That is worth stating because a certificate of analysis distinguishing the two is doing legal work rather than merely chemical work. Schedule 5 puts the row in the Articles 10, 41 and 57 branch, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Schedule 5 is one of the four schedule groups Article 57 names, and this entry is a Schedule 5 entry. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, and records that the Schedule 10 bands do not gate that route. Because both this compound and the N-methylated one sit in Schedule 5, the identification question that matters chemically does not change the article that applies, but it does still have to be answered correctly before anything is said about the row at all. Article 41 carries the personal use route for this branch, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: the Schedule 5 placement at the entry «MDA؛ ميثيلين ديوكسي أمفيتامين», with no medicinal product, research authorisation or prescribing route recorded against it. The medical question is deferred rather than reasoned out of the branch.
Documentation: No documentation route is recorded for this substance. Provenance: the Schedule 5 placement and the entry «MDA؛ ميثيلين ديوكسي أمفيتامين» were read on 20 September 2026, and the capital analysis rests on Article 57 rather than on the Schedule 10 bands. The practical point is that material sold under a name that could describe either this compound or the N-methylated one is not documented by that name, and only an analysis identifies which entry is engaged.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, printed entry «MDA؛ ميثيلين ديوكسي أمفيتامين», a separate enumerated entry from the N-methylated compound carried in the same schedule · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=MDA and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

MDA in United Arab Emirates, full detail →

MDMA

Legal status: Midomafetamine is placed in Schedule 5 of Decision No. 158 of 2025 at the printed entry «MDMA؛ ميثيلين ديوكسي ميثامفيتامين», which carries the abbreviation together with the Arabic methylenedioxy methamphetamine description. The placement is in the first psychotropic schedule, not in the Schedule 6 branch that carries the plain methamphetamine entry, so the methylenedioxy compound and the parent stimulant are on different articles in this instrument despite the shared name fragment. Anyone reasoning from the word methamphetamine in the entry to the methamphetamine row's treatment would land on the wrong article. The row runs through Articles 10, 41 and 57, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Schedule 5 is one of the four schedule groups Article 57 names, and this entry is in Schedule 5, so the row carries the mandatory death formulation rather than the death or life alternative that Article 58 gives the Schedule 6 to 8 group. The dossier records Article 57 as stating no quantity for its trafficking or promotion trigger, and records that the Schedule 10 bands do not gate the route. A tablet count is therefore not the variable it would be in most jurisdictions, because the article that carries the capital exposure contains no count at all. Article 41 carries the personal use route for this branch, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: the Schedule 5 placement at «MDMA؛ ميثيلين ديوكسي ميثامفيتامين», with no medicinal product, trial authorisation or prescribing route recorded against it. Therapeutic programmes for this compound exist in other jurisdictions and the dossier records nothing extending them here, so the question is deferred rather than inferred.
Documentation: No documentation route is recorded for this substance, and participation in a trial or programme elsewhere is not an Emirati authorisation on this record. Provenance: the Schedule 5 placement and the entry «MDMA؛ ميثيلين ديوكسي ميثامفيتامين» were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. The point worth carrying is the schedule split: this compound is Schedule 5 and Article 57, while the parent stimulant it is named after is Schedule 6 and Article 58.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, printed entry «MDMA؛ ميثيلين ديوكسي ميثامفيتامين», placed in the first psychotropic schedule and not in the Schedule 6 branch that carries the plain methamphetamine entry · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=MDMA and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

MDMA in United Arab Emirates, full detail →

MDPV

Legal status: This compound is named in the cathinones block of Schedule 5 of Decision No. 158 of 2025, at item 3, subitem 25. The entry is «MDPV؛ 3،4-ميثيلين ديوكسي بيروفاليرون», and the dossier renders the chemical name as 3,4-Methylenedioxypyrovalerone. The enumeration is the point: the same schedule carries the parent alkaloid cathinone at its own entry, and the substituted members are listed individually in the item 3 block, so this row is controlled because subitem 25 names it and not because it is a cathinone derivative. The dossier's search on a neighbouring row records that the block prints some named analogues and not others, which is what an enumerated block looks like in practice. The row runs through Articles 10, 41 and 57, with Schedule 10 group 1 carrying the quantity band. The placement was read on 20 September 2026.
Consequences if caught: Item 3, subitem 25 of Schedule 5 puts this row in one of the four schedule groups Article 57 names. The dossier records the article as stating mandatory death for its trafficking or promotion trigger and as stating no quantity, so the capital exposure follows from the subitem placement and the conduct. Schedule 10 assigns a group 1 band to the substance, and the dossier records that the bands do not gate the Article 57 route, so the band is not the threshold it looks like. On a substituted cathinone this matters twice over, because the question that decides the row is which member was proved rather than how much of it there was. Article 41 carries the personal use route for this branch, with no tariff stated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: the placement at Schedule 5, item 3, subitem 25, with no medicinal product or prescribing route recorded against it. No permit procedure is described for the Schedule 5 branch, so the medical question is deferred rather than answered.
Documentation: No documentation route is recorded for this substance. Provenance: the entry «MDPV؛ 3،4-ميثيلين ديوكسي بيروفاليرون» at item 3, subitem 25 was read on 20 September 2026, with the capital analysis resting on Article 57 and not on the group 1 band. The practical point is that material described only as a synthetic cathinone is not placed by this row, because the block names its members and a member it does not name is a separate question.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, item 3 (cathinones), subitem 25, printed entry «MDPV؛ 3،4-ميثيلين ديوكسي بيروفاليرون», an enumerated member of the cathinones block rather than a substance reached by the parent cathinone entry · Articles 10, 41 and 57 attach to this branch and the Schedule 10 group 1 band does not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=MDPV and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English chemical rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

MDPV in United Arab Emirates, full detail →

Mephedrone (4-MMC)

Legal status: Mephedrone is named in the cathinones block of Schedule 5 of Decision No. 158 of 2025, at item 3, subitem 26. The entry is «ميفيدرون؛ 4-MMC؛ 4-ميثيل ميثكاثينون», printing the name, the abbreviation and the 4-methyl methcathinone description together, so the ring position is part of the entry itself. That is the decisive detail on this row: the dossier's search on the 3-methyl isomer records that the same block prints other named analogues but not that one, so the block is controlling the 4-methyl compound by name rather than controlling methylmethcathinones as a family. A substance proved to be a different ring isomer is therefore not answered by this entry. The row runs through Articles 10, 41 and 57, with Schedule 10 group 1 carrying the quantity band. The placement was read on 20 September 2026.
Consequences if caught: Item 3, subitem 26 of Schedule 5 places mephedrone in one of the four schedule groups Article 57 names. The dossier records the article as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, and records that the Schedule 10 group 1 band does not gate that route. The forensic question on this row is the ring position rather than the weight, because the entry names the 4-methyl compound: being the printed isomer is what engages a quantity free capital route, and being a different isomer leaves the row unplaced by this entry. Article 41 carries the personal use route for this branch, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: mephedrone is at Schedule 5, item 3, subitem 26, with no medicinal product or prescribing route recorded against it. No permit procedure is given for the branch, so the medical question is deferred rather than answered.
Documentation: No documentation route is recorded for mephedrone. Provenance: the entry «ميفيدرون؛ 4-MMC؛ 4-ميثيل ميثكاثينون» at item 3, subitem 26 was read on 20 September 2026, with the capital analysis resting on Article 57 and not on the group 1 band. The point worth carrying is that the entry prints the 4-methyl position, so a laboratory result naming a different methylmethcathinone is describing a substance this row does not place.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, item 3 (cathinones), subitem 26, printed entry «ميفيدرون؛ 4-MMC؛ 4-ميثيل ميثكاثينون» for mephedrone, the entry naming the 4-methyl position · Articles 10, 41 and 57 attach to this branch and the Schedule 10 group 1 band does not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%85%D9%8A%D9%81%D9%8A%D8%AF%D8%B1%D9%88%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Mephedrone (4-MMC) in United Arab Emirates, full detail →

Mescaline

Legal status: Mescaline is placed in Schedule 5 of Decision No. 158 of 2025 at the printed entry «مسكالين». The entry is the compound's own, with no plant limb attached to it, and the dossier records the plant side of the question as running separately through Article 14, which reaches a plant producing a narcotic or psychotropic substance. So there are two routes on this subject and they are not the same route: the alkaloid is placed by its Schedule 5 entry, and cactus material is reached, where it is reached, by the plant provision. The dossier resolves the peyote row that way rather than by treating the cactus as a scheduled entry. This row runs through Articles 10, 41 and 57, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Schedule 5 is one of the four schedule groups Article 57 names, and the «مسكالين» entry is in Schedule 5, so the isolated alkaloid carries the capital route. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity, and records that the Schedule 10 bands do not gate it. Where the material is plant rather than alkaloid, the dossier's route is Article 14 rather than this entry, and that difference is worth preserving: one is a substance placement and the other is a provision about plants, and reporting them as a single fact hides which one a given case turns on. Article 41 carries the personal use route for this branch, with its tariff unstated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: mescaline is in Schedule 5 at its own compound entry, and no medicinal product, research authorisation or prescribing route is recorded against it. No ceremonial or cultural allowance appears anywhere in the dossier for this substance, so the question of a lawful route is deferred.
Documentation: No documentation route is recorded for mescaline. Provenance: the Schedule 5 placement and the entry «مسكالين» were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. The point worth carrying is that this entry is the alkaloid's, so a question about dried or live cactus material is answered through the Article 14 plant route and should be asked in those terms rather than by citing this placement.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, printed entry «مسكالين» for mescaline, the compound's own entry, with plant material reached separately through the Article 14 plant provision · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%85%D8%B3%D9%83%D8%A7%D9%84%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Mescaline in United Arab Emirates, full detail →

Methadone

Legal status: Methadone is placed in Schedule 1 of Decision No. 158 of 2025 at the printed entry «ميثادون». The dossier's finding is that a lawful medical treatment route exists for the substance while the Schedule 1 placement continues to govern unauthorised handling, so the two do not cancel out: being a treatment drug describes what it is used for and does not move where it sits. That is the structural point for every opioid substitution question in this country, because the medicine a patient is stabilised on is in the narcotics schedule proper rather than in a medicines tier. The dossier attaches Articles 10, 41 and 57 and states the content of Article 57 only. Schedule 10 carries the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Schedule 1 is one of the four schedule groups Article 57 names, and methadone's entry is in Schedule 1. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, and records that the Schedule 10 bands do not gate that route. Because the article contains no quantity, a take home supply large enough to cover a trip is not a different legal quantity from a small one on that article, and what separates lawful from unlawful is the authorisation and the conduct rather than the volume. Article 41 carries the personal use route for this branch, with no tariff stated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: methadone is in Schedule 1, and the dossier records that a lawful medical treatment route exists for it without describing the route, the authorisation that carries it or any traveller procedure. That gap is the material one for a patient on a maintenance programme, and the dossier does not close it, so the question of what an Emirati authorisation would require is deferred rather than answered.
Documentation: Carry the prescription, the original dispensing packaging and a letter from the prescribing service naming the patient, the daily dose and the treatment period, and settle the permit question with the health ministry before travelling rather than at the border, because the dossier records no Emirati permit procedure. Provenance: the Schedule 1 placement and the entry «ميثادون» were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. A maintenance patient is the traveller most exposed by the gap between a treatment route existing and its terms not being recorded.

United Arab Emirates, Decision No. 158 of 2025, Schedule 1, printed entry «ميثادون» for methadone, the dossier recording a lawful medical treatment route without stating its terms while the Schedule 1 placement continues to govern unauthorised handling · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%85%D9%8A%D8%AB%D8%A7%D8%AF%D9%88%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Methadone in United Arab Emirates, full detail →

Methamphetamine

Legal status: Methamphetamine is placed in Schedule 6 of Decision No. 158 of 2025, the psychotropic Schedule II equivalent branch, at the printed entry «ميثامفيتامين». The dossier's finding is that this placement sends the row to the Article 58 trafficking branch. That is the counterintuitive fact on this cell and it should not be smoothed away: the substance most readers would expect to sit at the top of the scheduling is in the psychotropic branch here, alongside amphetamine, while the methylenedioxy compound named after it is in Schedule 5 on the harsher article. Scheduling in this instrument follows the narcotic and psychotropic division rather than a ranking by perceived harm. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and methamphetamine is in Schedule 6, so that article and not Article 57 is the capital route for this row. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary rather than mandatory, and it records that the article states no quantity. The Schedule 10 bands do not gate that route. The discretionary wording is a genuine difference from the Article 57 rows and it is not a reduction in exposure: the ceiling is the same and only the compulsion differs. Article 43 carries the personal use route for this branch, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: methamphetamine is in Schedule 6, and the dossier records no medicinal product, prescribing route or permit procedure against that entry. Methamphetamine is a licensed medicine in a small number of health systems, and nothing in the dossier extends that to the Emirati placement, so the question is deferred rather than inferred.
Documentation: No documentation route is recorded for methamphetamine in this dossier, so on this record there is nothing that would make carriage lawful. Provenance: the Schedule 6 placement and the entry «ميثامفيتامين» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative rather than on the Schedule 10 bands. The point worth carrying is the schedule division: this substance is Schedule 6 and Article 58, while several substances a reader would rank as less serious are Schedule 5 and Article 57.

United Arab Emirates, Decision No. 158 of 2025, Schedule 6 (psychotropic Schedule II equivalent), printed entry «ميثامفيتامين» for methamphetamine, placed in the psychotropic branch rather than with the Schedule 5 substances that carry Article 57 · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 bands do not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%85%D9%8A%D8%AB%D8%A7%D9%85%D9%81%D9%8A%D8%AA%D8%A7%D9%85%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Methamphetamine in United Arab Emirates, full detail →

Methaqualone (Quaaludes)

Legal status: Methaqualone is scheduled in Schedule 6 of Decision No. 158 of 2025 at the printed entry «ميثاكوالون». The dossier records that the Schedule 6 group carries the Schedule 3, 6, 7 and 8 quantity bands, which is the structural fact behind this row: the quinazolinone sedative sits in the psychotropic branch rather than with the narcotics, and its penalty architecture follows that branch throughout. Methaqualone was withdrawn from medical use in most countries decades ago, so unlike the benzodiazepine rows in the same schedule there is no current prescribing practice behind this entry, and the placement is doing purely prohibitive work. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and methaqualone is in Schedule 6, so the article applies to the row. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary rather than mandatory, and it records that the article states no quantity. The Schedule 10 bands do not gate that route. Material circulating under this name is usually tablets of uncertain composition, and that is a forensic problem rather than a legal one here: the entry places the substance, so what matters is what an analysis finds rather than what a tablet was sold as. Article 43 carries the personal use route, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: the Schedule 6 placement at «ميثاكوالون», with no current medicinal product recorded behind it in the dossier and no prescribing route or permit procedure given. The medical question is therefore not simply deferred for want of a procedure, there is also nothing in the dossier suggesting a lawful medical use to which a procedure would attach.
Documentation: No documentation route is recorded for methaqualone. Provenance: the Schedule 6 placement and the entry «ميثاكوالون» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative rather than on the Schedule 10 bands. The practical point is that tablets sold under the street names associated with this substance frequently contain something else, and the analysis rather than the name decides which entry, if any, applies.

United Arab Emirates, Decision No. 158 of 2025, Schedule 6 (psychotropic Schedule II equivalent), printed entry «ميثاكوالون» for methaqualone, the dossier recording that the Schedule 6 group carries the Schedule 3, 6, 7 and 8 quantity bands · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 bands do not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%85%D9%8A%D8%AB%D8%A7%D9%83%D9%88%D8%A7%D9%84%D9%88%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Methaqualone (Quaaludes) in United Arab Emirates, full detail →

Methylone

Legal status: Methylone is listed in the cathinones block of Schedule 5 of Decision No. 158 of 2025, at item 3, subitem 29. The entry is «ميثيلون», and the dossier records the accompanying chemical name as 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)propan-1-one. The benzodioxole ring in that name is what connects and separates this row from the methylenedioxy amphetamines carried elsewhere in the same schedule: the ring system is shared and the ketone is not, and the schedule resolves the point by enumerating this substance in the cathinones block rather than with the amphetamines. Placement by enumeration is the pattern throughout Schedule 5, so what controls is subitem 29 naming it. The row runs through Articles 10, 41 and 57, with Schedule 10 group 1 carrying the quantity band. The placement was read on 20 September 2026.
Consequences if caught: Item 3, subitem 29 of Schedule 5 sits in one of the four schedule groups Article 57 names. The dossier records the article as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, and records that the Schedule 10 group 1 band does not gate that route. So the capital exposure on this row is settled by identification and conduct, and the group 1 figure that does exist answers a separate question. Article 41 carries the personal use route for this branch, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: methylone is at Schedule 5, item 3, subitem 29, with no medicinal product or prescribing route recorded against it. The medical question is deferred rather than reasoned out of the Schedule 5 branch.
Documentation: No documentation route is recorded for methylone. Provenance: the entry «ميثيلون» at item 3, subitem 29 and the chemical name the dossier gives as 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)propan-1-one were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the group 1 band. The practical point is that this substance is enumerated among the cathinones rather than among the methylenedioxy amphetamines, so a report placing it by ring system alone has not identified the entry that applies.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, item 3 (cathinones), subitem 29, printed entry «ميثيلون» for methylone, the dossier rendering the chemical name as 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)propan-1-one · Articles 10, 41 and 57 attach to this branch and the Schedule 10 group 1 band does not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%85%D9%8A%D8%AB%D9%8A%D9%84%D9%88%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English chemical rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Methylone in United Arab Emirates, full detail →

Methylphenidate

Legal status: Methylphenidate is a Schedule 6 psychotropic under Decision No. 158 of 2025, at the printed entry «ميثيل فينيدات». The dossier's finding is that lawful prescribing for attention deficit disorders does not remove unauthorised conduct from the controlled substance framework, which is the shape of every prescribed stimulant row in this instrument: the permission and the prohibition sit side by side and the authorisation decides which applies. The entry names the substance rather than any product, so modified release and immediate release preparations are equally inside it. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The dossier states the content of Article 58 and does not state what Articles 11 and 43 provide. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and methylphenidate is in Schedule 6, so the article applies to a medicine prescribed to children and adults alike. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary rather than mandatory, and it records that the article states no quantity. The Schedule 10 bands do not gate that route. The realistic exposure on this row is not a trafficking scenario but a supply one, since passing a tablet to a classmate, a colleague or a family member is the kind of act a promotion trigger is written to reach, and no quantity threshold stands in front of it. Article 43 carries the personal use route, with its tariff unstated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: methylphenidate is in Schedule 6, and the dossier records lawful prescribing as compatible with the placement without describing any Emirati prescribing route, traveller allowance or permit procedure. For a family travelling with a child's prescription that gap is the whole of the practical question, and it is deferred here rather than filled by inference.
Documentation: Carry the prescription and the original dispensing packaging naming methylphenidate, together with a physician's letter identifying the patient and the daily dose, and settle the permit question with the health ministry before travelling because none is recorded in the dossier. Provenance: the Schedule 6 placement and the entry «ميثيل فينيدات» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative. Do not carry a supply for someone else, including a child travelling separately, without checking that question first.

United Arab Emirates, Decision No. 158 of 2025, Schedule 6 (psychotropic Schedule II equivalent), printed entry «ميثيل فينيدات» for methylphenidate, the entry naming the substance rather than any product presentation · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 bands do not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%85%D9%8A%D8%AB%D9%8A%D9%84%20%D9%81%D9%8A%D9%86%D9%8A%D8%AF%D8%A7%D8%AA and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Methylphenidate in United Arab Emirates, full detail →

Mitragynine

Legal status: Mitragynine is placed in Schedule 5 of Decision No. 158 of 2025 at item 20, the printed entry being «ميتراجينين». The entry is the alkaloid's alone, and the dossier's searches on two neighbouring rows make the boundary of it explicit: neither the plant name nor the trade name was found in the schedules, and neither was the 7-hydroxy metabolite. So item 20 names one compound, and this is the row where the United Arab Emirates position on the kratom family actually sits. The consequence is that the plant question and the alkaloid question have different answers on this record, and the alkaloid's answer is a placement in the first psychotropic schedule. The row runs through Articles 10, 41 and 57, with Schedule 10 group 1 carrying the quantity band. The placement was read on 20 September 2026.
Consequences if caught: Schedule 5 item 20 sits in one of the four schedule groups Article 57 names, so the isolated alkaloid carries the capital route. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, and records that the Schedule 10 group 1 band does not gate that route. The practical consequence for a plant derived product is severe and easy to miss: an extract standardised to this alkaloid is placed by the alkaloid entry whatever the leaf material's own status is, because the schedule names the compound. Article 41 carries the personal use route for this branch, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: mitragynine is at Schedule 5, item 20, with no medicinal product, supplement allowance or prescribing route recorded against it. Products sold abroad as herbal supplements are not placed outside the entry by being sold that way, and the dossier records no exemption, so the question of a lawful route is deferred.
Documentation: No documentation route is recorded for mitragynine, and a supplement label or an import declaration from another market is not an Emirati authorisation. Provenance: the entry «ميتراجينين» at Schedule 5, item 20 was read on 20 September 2026, with the capital analysis resting on Article 57 and not on the group 1 band. The point worth carrying is that the entry names the alkaloid, so a product's status here follows its assayed content rather than the plant or brand name on the packet.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, item 20, printed entry «ميتراجينين» for mitragynine, the alkaloid alone, with the plant name and the 7-hydroxy metabolite recorded as not found in the schedules · Articles 10, 41 and 57 attach to this branch and the Schedule 10 group 1 band does not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%85%D9%8A%D8%AA%D8%B1%D8%A7%D8%AC%D9%8A%D9%86%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Mitragynine in United Arab Emirates, full detail →

Morphine

Legal status: Morphine is placed in Schedule 1 of Decision No. 158 of 2025 at the printed entry «مورفين». Schedule 1 is the narcotics schedule proper, and the same schedule carries the diacetyl derivative at its own entry, so the medicinal opiate and the illicit one are placed together rather than in separate tiers. The entry itself is a bare designation with no preparations or strength limb printed beside it, which means an oral solution, a modified release tablet and an injectable ampoule are all reached by the same entry. The dossier attaches Articles 10, 41 and 57 and states the content of Article 57 only. Schedule 10 carries the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Schedule 1 is one of the four schedule groups Article 57 names, and morphine's entry is in Schedule 1, so the article reaches a palliative care medicine on the same terms as any other Schedule 1 substance. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity, and records that the Schedule 10 bands do not gate that route. The absence of a quantity is worth stating plainly on a medicinal opiate, because the intuition that a patient sized supply is categorically different from a trafficking quantity is a quantity intuition, and this article contains none. Article 41 carries the personal use route for this branch, with no tariff stated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: morphine is in Schedule 1 and the entry names the opiate without a preparations limb, so no strength or formulation falls outside it. The dossier records no prescribing route, no traveller allowance and no import permit procedure for morphine, so a patient's question about carrying a prescribed supply is precisely the question it does not answer, and it is deferred.
Documentation: Carry the prescription, the original dispensing packaging and a physician's letter naming the patient, the active ingredient, the dose and the treatment period, and raise the permit question with the health ministry before travelling, because no Emirati permit procedure is recorded in this dossier. Provenance: the Schedule 1 placement and the entry «مورفين» were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. Those documents are evidence about the medicine rather than an authorisation that moves it out of Schedule 1.

United Arab Emirates, Decision No. 158 of 2025, Schedule 1, printed entry «مورفين» for morphine, a bare designation reaching every preparation and strength · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%85%D9%88%D8%B1%D9%81%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Morphine in United Arab Emirates, full detail →

MXE

Legal status: Methoxetamine is listed at Schedule 6, item 10 of Decision No. 158 of 2025, at the printed entry «ميثوكسيتامين؛ MXE», and the dossier renders the chemical name as (RS)2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone. The dossier records that the substance commonly abbreviated MXE is the one this entry lists, so the abbreviation and the systematic name are tied together in the schedule rather than left to be matched afterwards. The item number places it in the same Schedule 6 sequence as the ketamine entry at item 7 and the fluoro analogue at item 3, three arylcyclohexylamines enumerated individually within ten items of one another. The row runs through Articles 11, 43 and 58, with Schedule 10 group 3 carrying the quantity band. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and this substance is at Schedule 6, item 10, so the article applies. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary rather than mandatory, and it records that the article states no quantity. The Schedule 10 group 3 band does not gate that route. This compound was marketed specifically as a legal substitute for the item 7 anaesthetic, and the enumeration is the answer to that marketing: it has its own item number, so the substitution argument has nowhere to run. Article 43 carries the personal use route for this branch, with its tariff unstated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: the placement at Schedule 6, item 10, with no medicinal product recorded behind it, unlike the ketamine entry three items earlier in the same schedule. No prescribing route or permit procedure is recorded, so the medical question is deferred rather than borrowed from the neighbouring entry.
Documentation: No documentation route is recorded for methoxetamine. Provenance: the entry «ميثوكسيتامين؛ MXE» at Schedule 6, item 10 was read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative rather than on the Schedule 10 group 3 band. The point worth carrying is that a vendor describing this compound as a lawful alternative to a scheduled anaesthetic is describing a substance that is itself scheduled at its own item number.

United Arab Emirates, Decision No. 158 of 2025, Schedule 6, item 10, printed entry «ميثوكسيتامين؛ MXE» for methoxetamine, the dossier rendering the chemical name as (RS)2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone, enumerated separately from the item 7 and item 3 arylcyclohexylamines in the same schedule · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 group 3 band does not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%85%D9%8A%D8%AB%D9%88%D9%83%D8%B3%D9%8A%D8%AA%D8%A7%D9%85%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English chemical rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

MXE in United Arab Emirates, full detail →

Nicotine

Legal status: Nicotine is regulated through tobacco and nicotine product law rather than being classified as a narcotic or psychotropic. The dossier ran a completed non reach search across Schedules 1 to 9 of Decision No. 158 of 2025 for «نيكوتين» and recorded no narcotic or psychotropic entry, and it names the controlling federal instrument on this row as Federal Decree-Law 30 of 2021, the only row in the whole dossier where that instrument is named in words rather than cited by article number. Nicotine is the substance in this row rather than the leaf, so vaping liquids, pouches and replacement therapies are all nicotine products and the applicable regime is the same for each, though the dossier does not record its terms. The search was run on 20 September 2026.
Consequences if caught: Capital exposure: none. Decision No. 158 of 2025 Schedules 1 to 8 do not reach nicotine, so Articles 57 and 58 do not attach and no narcotics quantity applies. Any consequence comes from the federal tobacco and nicotine product regime instead, which is not a narcotics capital provision and whose sanctions the dossier does not record. The point to be careful about is that a product restriction under that regime, for instance on a particular device or strength, is a different kind of rule from a schedule placement and it cannot be read off this table.
If prescribed / medical: No narcotics prescription question arises for nicotine, since it is outside Decision No. 158 of 2025 and there is no drug authorisation to seek. The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule, which does not bear on this row either. Nicotine replacement products are medicines in many markets, and the rules that would govern them here belong to the tobacco and nicotine product regime rather than to the drug schedules.
Documentation: No drug law documentation applies to nicotine. Provenance: the completed Schedules 1 to 9 non reach search on «نيكوتين» was run on 20 September 2026. What a traveller should establish before arriving concerns the tobacco and nicotine product rules, including anything specific to vaping devices and liquid strengths, and the dossier does not record those, so they need a current official source rather than an inference from this cell.

United Arab Emirates, Decision No. 158 of 2025, completed Schedules 1 to 9 non reach search for «نيكوتين», nicotine, returning no narcotic or psychotropic entry, the dossier naming Federal Decree-Law 30 of 2021 as the federal drug instrument on this row and the federal tobacco and nicotine product regime as governing instead, its terms not recorded · the schedules were read at https://sha.shj.ae/#:~:text=%D8%A7%D9%84%D8%AC%D8%AF%D8%A7%D9%88%D9%84%20%D8%A7%D9%84%D9%85%D8%B1%D9%81%D9%82%D8%A9 and the federal instrument at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D9%86%D9%8A%D9%83%D9%88%D8%AA%D9%8A%D9%86, the federal legislation portal · the instrument is written in Arabic and the English renderings are the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Nicotine in United Arab Emirates, full detail →

Nimetazepam

Legal status: Nimetazepam is an individually listed Schedule 8 psychotropic under Decision No. 158 of 2025, at the printed entry «نيميتازيبام». The dossier's finding is that it is not assigned a class wide benzodiazepine result, and on this member that is a substantive point rather than a formality: nimetazepam is not licensed in most markets and circulates chiefly as an illicit tablet, so a class rule would be the only way to reach it in a country that did not name it. This instrument names it, which is why the placement holds independently of anything said about the other five members. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and nimetazepam is in Schedule 8, so the article applies to the row. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary rather than mandatory, and it records that the article states no quantity. The Schedule 10 bands do not gate that route. Because this member circulates almost entirely as an illicit tablet rather than as a dispensed medicine, the trafficking and promotion trigger is the realistic exposure here rather than a prescription question, and it carries a capital ceiling with no threshold in front of it. Article 43 carries the personal use route, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: nimetazepam is named individually in Schedule 8. The dossier records no medicinal product, prescribing route or permit procedure for it, and unlike the other benzodiazepine members in this table there is no widespread licensed product behind the entry, so the question of a lawful medical route is deferred and is unlikely to arise in the form it takes for the other members.
Documentation: No documentation route is recorded for nimetazepam, and tablets obtained without a prescription have no paperwork that would assist. Provenance: the Schedule 8 placement and the entry «نيميتازيبام» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative rather than on the Schedule 10 bands. If the medicine was dispensed under a licence somewhere it is held, carry the prescription and the original packaging, and put the permit question to the health ministry before departure.

United Arab Emirates, Decision No. 158 of 2025, Schedule 8, printed entry «نيميتازيبام» for nimetazepam, individually listed rather than reached by a class wide benzodiazepine rule · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 bands do not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%86%D9%8A%D9%85%D9%8A%D8%AA%D8%A7%D8%B2%D9%8A%D8%A8%D8%A7%D9%85 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Nimetazepam in United Arab Emirates, full detail →

Nitrous Oxide

Legal status: Nitrous oxide is not treated as a scheduled narcotic on this record, and the dossier is explicit that it is not being read into one from a traveller list. The name «أكسيد النيتروز» was searched and no Schedule 1 to 8 placement was found. The route the dossier records instead is the conduct based control at Article 12(2) with Article 44, quoted as «أية مادة أو نبات من غير المواد المخدرة أو المؤثرات العقلية... يكون من شأنها إحداث التخدير أو أي أثر آخر ضار بالعقل», any substance or plant other than the narcotics and psychotropic substances capable of causing intoxication or another effect harmful to the mind. Recreational use for intoxication is what can engage that functional rule, while the same gas in a clinical, catering or industrial context is not placed by it. The record was read on 20 September 2026.
Consequences if caught: Capital exposure: none. This row is reached through Articles 12(2) and 44 rather than by a Schedule 1 to 8 placement, Article 44 is non capital, Articles 57 and 58 do not attach, and no capital quantity applies. The variable on this route is the purpose rather than the quantity or the container, which means a canister count tells you nothing about the legal position, in contrast to the scheduled rows in this table where identity settles it. The dossier does not state Article 44's tariff, so no penalty figure is given here.
If prescribed / medical: There is no schedule placement for nitrous oxide and therefore no narcotics authorisation to obtain. The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule, and this row in particular is one the dossier declines to resolve from any such list. Medical and food grade nitrous oxide are regulated by the regimes that cover medicines and food products, and the dossier does not record their terms.
Documentation: No documentation route is recorded for nitrous oxide, and none would be expected for a conduct based rule. Provenance: the name search «أكسيد النيتروز» and the Article 12(2) with Article 44 route were read on 20 September 2026. The point worth carrying is that the gas is lawful in medical, catering and industrial use and the rule that can reach it looks at the purpose of possession, so the presence of canisters or a dispenser is not itself the question.

United Arab Emirates, Decision No. 158 of 2025 carries no nitrous oxide entry after the name search «أكسيد النيتروز», and the dossier declines to resolve the row from a traveller list · it is reached, if at all, through the conduct based control at Article 12(2) with Article 44, quoted as «أية مادة أو نبات من غير المواد المخدرة أو المؤثرات العقلية... يكون من شأنها إحداث التخدير أو أي أثر آخر ضار بالعقل» · Article 44 is non capital and Articles 57 and 58 do not attach · read at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A3%D9%8A%D8%A9%20%D9%85%D8%A7%D8%AF%D8%A9%20%D8%A3%D9%88%20%D9%86%D8%A8%D8%A7%D8%AA%20%D9%85%D9%86%20%D8%BA%D9%8A%D8%B1%20%D8%A7%D9%84%D9%85%D9%88%D8%A7%D8%AF%20%D8%A7%D9%84%D9%85%D8%AE%D8%AF%D8%B1%D8%A9%20%D8%A3%D9%88%20%D8%A7%D9%84%D9%85%D8%A4%D8%AB%D8%B1%D8%A7%D8%AA%20%D8%A7%D9%84%D8%B9%D9%82%D9%84%D9%8A%D8%A9, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Nitrous Oxide in United Arab Emirates, full detail →

Opium

Legal status: Opium is carried at the Schedule 1 opium entry of Decision No. 158 of 2025, the printed entry being «الأفيون». The dossier's finding is that it is controlled as a narcotic rather than as a traditional preparation, which places unauthorised conduct inside the Schedule 1 penalty architecture rather than in any customary or cultural category. The entry is the raw material itself, and the same schedule separately carries the alkaloids refined from it, so a placement question about opium and a placement question about morphine are answered by different entries even though the substances are related by extraction. The row runs through Articles 10, 41 and 57, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Schedule 1 is one of the four schedule groups Article 57 names, and the «الأفيون» entry is in Schedule 1. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, and records that the Schedule 10 bands do not gate that route. On a raw plant product the absence of a quantity has an added edge, because bulk is inherent to the material and a reader reasoning from volume will reason about a variable the article does not use. Article 41 carries the personal use route for this branch, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: opium sits at the Schedule 1 opium entry, and the dossier records no medicinal opium preparation, prescribing route or permit against it. Preparations containing opium are dispensed in some health systems and the dossier extends nothing from those to this placement, so the question is deferred rather than assumed.
Documentation: No document recorded in this dossier makes carriage of opium lawful, and customary or traditional use in another country is not an Emirati authorisation. Provenance: the Schedule 1 opium entry «الأفيون» was read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. A traveller carrying a preparation said to contain opium has a question the dossier does not answer, and it belongs with the health ministry before departure.

United Arab Emirates, Decision No. 158 of 2025, Schedule 1 opium entry, printed entry «الأفيون» for opium, the raw material carried separately from the alkaloids refined from it · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%A7%D9%84%D8%A3%D9%81%D9%8A%D9%88%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Opium in United Arab Emirates, full detail →

Oxycodone

Legal status: Oxycodone is placed in Schedule 1 of Decision No. 158 of 2025 at the printed entry «أوكسيكودون». The dossier's finding is that its prescription status does not convert unauthorised possession or trafficking into an ordinary medicines offence: the substance is in the narcotics schedule proper, so the schedule based route governs whatever the tablet was originally dispensed for. The entry is a bare designation, so modified release and immediate release products, and combinations containing the opioid, are all inside it. The row runs through Articles 10, 41 and 57, with Schedule 10 carrying the quantity bands. The dossier states the content of Article 57 and does not state what Articles 10 and 41 provide. The placement was read on 20 September 2026.
Consequences if caught: Schedule 1 is one of the four schedule groups Article 57 names, and the «أوكسيكودون» entry is in Schedule 1. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, and records that the Schedule 10 bands do not gate that route. Supplying tablets to another person is the conduct most likely to be misjudged on this row, because it is commonplace with prescribed analgesics and it is the kind of act a promotion or trafficking trigger is written to reach, with no quantity threshold standing between it and the article. Article 41 carries the personal use route for this branch, with no tariff stated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: oxycodone is in Schedule 1 and no strength, formulation or pack size falls outside the entry. The dossier records no prescribing route, no traveller allowance and no import permit procedure, so a patient's question about bringing a prescribed supply is deferred rather than answered, and it should not be inferred from the fact that the medicine is lawfully dispensed elsewhere.
Documentation: Carry the prescription and the original dispensing packaging naming the active ingredient, together with a physician's letter, and settle the permit question with the health ministry before travelling because no Emirati permit procedure is recorded here. Provenance: the Schedule 1 placement and the entry «أوكسيكودون» were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. Do not give tablets to a travelling companion, since that is the act most likely to move the row from a possession question to a supply one.

United Arab Emirates, Decision No. 158 of 2025, Schedule 1, printed entry «أوكسيكودون» for oxycodone, a bare designation reaching every formulation and combination · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%A3%D9%88%D9%83%D8%B3%D9%8A%D9%83%D9%88%D8%AF%D9%88%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Oxycodone in United Arab Emirates, full detail →

PCP

Legal status: Phencyclidine is a Schedule 6 psychotropic under Decision No. 158 of 2025, at the printed entry «فينسيكليدين؛ PCP», which prints the Arabic form of the chemical name together with the abbreviation. The dossier records that the row therefore uses Article 58 plus the Schedule 3, 6, 7 and 8 quantity ladder. The placement puts phencyclidine in the same schedule as the three arylcyclohexylamines enumerated at items 3, 7 and 10 of that schedule, which is coherent: the instrument keeps this structural family together in the psychotropic branch rather than distributing it. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and phencyclidine is in Schedule 6, so the article applies to the row. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary rather than mandatory, and it records that the article states no quantity. The Schedule 10 bands do not gate that route, so the quantity ladder that does apply to the Schedule 3, 6, 7 and 8 group answers something other than the capital question. Material sold under this name is frequently applied to plant material rather than carried as a powder, and the entry places the substance wherever it is found. Article 43 carries the personal use route, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: the Schedule 6 placement at «فينسيكليدين؛ PCP», with no current medicinal product recorded behind it in the dossier, in contrast to the ketamine entry in the same schedule. No prescribing route or permit procedure is recorded, so the medical question is deferred.
Documentation: No documentation route is recorded for phencyclidine. Provenance: the Schedule 6 placement and the entry «فينسيكليدين؛ PCP» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative rather than on the Schedule 10 bands. The practical point is that the substance is often carried on treated plant material, so the physical form gives no indication of what an analysis will identify, and the entry attaches to the compound rather than to the presentation.

United Arab Emirates, Decision No. 158 of 2025, Schedule 6 (psychotropic Schedule II equivalent), printed entry «فينسيكليدين؛ PCP» for phencyclidine, in the same schedule as the arylcyclohexylamines enumerated at items 3, 7 and 10 · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 bands do not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%81%D9%8A%D9%86%D8%B3%D9%8A%D9%83%D9%84%D9%8A%D8%AF%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

PCP in United Arab Emirates, full detail →

Peyote

Legal status: The peyote cactus is reached because of what it produces, and the alkaloid, mescaline, is reached because it is scheduled. Peyote has no cactus entry of its own in Decision No. 158 of 2025. The two joined routes rely on the entry «مسكالين في صبار البيوت»: Article 14 reaches any plant producing a narcotic or psychotropic substance, and mescaline itself is placed in Schedule 5. Keeping the two apart matters, because the plant route depends on the production fact being established and the alkaloid route does not. Article 57 attaches where the proved route is the Schedule 5 mescaline entry or the Article 14 plant route. The placement was read on 20 September 2026.
Consequences if caught: The capital route on this row runs through Article 57, and the dossier is careful about when: it attaches where the proved route is the Schedule 5 mescaline entry or the Article 14 plant provision reaching a plant that produces a controlled psychotropic. Article 57 is recorded as stating mandatory death for its trafficking or promotion trigger and as stating no quantity, so once either route is proved there is no threshold standing in front of it. The conditional is the honest part of this cell rather than a hedge: the exposure is real and it depends on establishing what the material is or what it produces, and a cell that asserted it unconditionally would be describing a cactus entry that does not exist. No quantity of plant material is stated anywhere in the analysis and none is inferred.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: peyote is not itself scheduled, and the placement relied on is mescaline's in Schedule 5 together with the Article 14 plant provision, so there is no cactus entry for a prescription or permit to attach to. No ceremonial or religious exemption is recorded in the dossier, and none is inferred here.
Documentation: No documentation route is recorded for peyote, and a ceremonial or religious use permitted elsewhere is not an Emirati authorisation on this record. Provenance: the route relied on, «مسكالين في صبار البيوت» with Article 14 and the Schedule 5 mescaline entry, was read on 20 September 2026. The practical point is that dried buttons, live plant material and an extract are all answered by what they produce or contain rather than by the name given to them, and none of the three is documented by a certificate of origin.

United Arab Emirates, Decision No. 158 of 2025, no peyote entry · the row is resolved through the Article 14 plant provision reaching a plant that produces a controlled psychotropic together with the Schedule 5 mescaline entry, recorded at «مسكالين في صبار البيوت» · Article 57 attaches where either of those routes is the proved one and states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=%D9%85%D8%B3%D9%83%D8%A7%D9%84%D9%8A%D9%86%20%D9%81%D9%8A%20%D8%B5%D8%A8%D8%A7%D8%B1%20%D8%A7%D9%84%D8%A8%D9%8A%D9%88%D8%AA and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated October 8, 2026

Peyote in United Arab Emirates, full detail →

Pink Cocaine / Tusi

Legal status: Pink cocaine is not the name of a single chemical substance but a variable street mixture, and the Emirati result follows each proved constituent. That is the settled treatment of this label rather than an unfinished answer. The complete schedules of Decision No. 158 of 2025 were the instrument checked, and the determination is that the label does not map to an entry in them. The label «الكوكايين الوردي؛ توسي» is not the name of one chemical substance in the schedules, and there is no label wide placement to give. In practice the powders sold under this name are most often a mixture, and the names that appear in analyses of them, ketamine at Schedule 6, item 7 and the methylenedioxy compounds in Schedule 5, are placed in different schedules under different articles, which is precisely why the label cannot carry one answer. The determination was made on 20 September 2026.
Consequences if caught: Capital exposure: not established. That is a property of the label rather than an open question about a substance: each proved constituent must be classified first, and the constituent's own schedule then determines whether Article 57, Article 58 or no capital route applies, so no label wide capital quantity can be stated. The spread is wide and it is the point. A constituent in Schedules 1, 2, 4 Section I or 5 brings Article 57, which the dossier records as stating mandatory death for its trafficking or promotion trigger with no quantity. A constituent in Schedules 3, 6, 7 or 8 brings Article 58, recorded as death or life imprisonment in the alternative, also with no quantity. Two powders sold under the same name can therefore sit on different articles, and neither outcome can be read off the name.
If prescribed / medical: No prescription question attaches to a street mixture label, because there is no entry for a prescription or a permit to evidence and no medicinal product behind the name. The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule, which has no bearing here. Any medical question would belong to a proved constituent and would be answered on that constituent's row.
Documentation: There is nothing to document for a label of this kind. Provenance: the constituent specific determination against the complete Decision No. 158 of 2025 schedules, recorded at «الكوكايين الوردي؛ توسي», was made on 20 September 2026. The single practical point is that a buyer does not know what is in the powder, and the legal position follows what an analysis finds rather than what it was sold as, so the label offers no basis for any expectation at all.

United Arab Emirates, Decision No. 158 of 2025, complete schedules · constituent specific determination for the variable street mixture label recorded at «الكوكايين الوردي؛ توسي», which the dossier records as not being the name of one chemical substance in the schedules · each proved constituent is classified first and its schedule then determines whether Article 57, Article 58 or no capital route applies, so no label wide capital quantity can be stated · read at https://sha.shj.ae/#:~:text=%D8%A7%D9%84%D8%AC%D8%AF%D8%A7%D9%88%D9%84%20%D8%A7%D9%84%D9%85%D8%B1%D9%81%D9%82%D8%A9 · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated October 8, 2026

Pink Cocaine / Tusi in United Arab Emirates, full detail →

Poppers

Legal status: Poppers is a product class label covering a group of alkyl nitrites, not the name of a single chemical substance, and that is the settled treatment of the label here. The dossier records «بوبرز؛ نتريتات الألكيل» as a label that is not one chemical entry in the schedules, so the Emirati result follows each proved constituent. The complete schedules of Decision No. 158 of 2025 were the instrument checked. The amyl nitrite row in this table shows what a constituent answer looks like: that named nitrite was searched, returned no Schedule 1 to 8 placement, and is reached instead, if at all, through the conduct based control at Article 12(2) with Article 44. Another alkyl nitrite in a bottle sold under this label would have to be checked in the same way rather than assumed to follow. The determination was made on 20 September 2026.
Consequences if caught: Capital exposure: not established. That is a property of the label: each proved constituent must be classified first, and the constituent's schedule then determines whether Article 57, Article 58 or no capital route applies, so no label wide capital quantity can be stated. On the constituent this table does carry, the amyl nitrite row, no schedule placement was returned and the route recorded is the conduct based Article 12(2) with Article 44, which is non capital. That is one constituent's answer and not the label's, and a bottle whose contents are a different nitrite has not been placed by it.
If prescribed / medical: No prescription question attaches to a product class label, since there is no entry for a prescription or a permit to evidence. The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule, which has no bearing here. Where a specific alkyl nitrite has a medicinal history, the question belongs on that constituent's row and is answered there.
Documentation: There is nothing to document for a product class label. Provenance: the constituent specific determination against the complete Decision No. 158 of 2025 schedules, recorded at «بوبرز؛ نتريتات الألكيل», was made on 20 September 2026. The practical point is that bottles sold under this label rarely state which nitrite they contain, and since the answer follows the constituent, the label on the bottle is not the information the question needs.

United Arab Emirates, Decision No. 158 of 2025, complete schedules · constituent specific determination for the product class label recorded at «بوبرز؛ نتريتات الألكيل», which the dossier records as not being one chemical entry in the schedules · each proved constituent is classified first and its schedule then determines whether Article 57, Article 58 or no capital route applies, so no label wide capital quantity can be stated · the amyl nitrite constituent carried in this table returned no Schedule 1 to 8 placement and is reached, if at all, through the non capital conduct route at Article 12(2) with Article 44 · read at https://sha.shj.ae/#:~:text=%D8%A7%D9%84%D8%AC%D8%AF%D8%A7%D9%88%D9%84%20%D8%A7%D9%84%D9%85%D8%B1%D9%81%D9%82%D8%A9 · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Poppers in United Arab Emirates, full detail →

Pregabalin

Legal status: Pregabalin is placed at Schedule 9, item 18 of Decision No. 158 of 2025, at the printed entry «بريجابالين», where the instrument states 600 mg daily. The dossier's finding is precise and it is the whole of the row: pregabalin is in Schedule 9 and it is not placed in Schedules 1 through 8. Schedule 9 is where this instrument records quantities for controlled medicines, and it lies outside the schedules named by the two trafficking articles, so the substance is controlled without being inside either article's group. That makes this the only row in this table with a quantity attached to it and no capital route, which is the inverse of every scheduled row, where the capital route is quantity free. The placement was read on 20 September 2026.
Consequences if caught: Capital exposure: none. This row is in Schedule 9, which is outside the schedules named by Articles 57 and 58, so neither article attaches. Its printed daily quantity of 600 mg is a control limit and not a death threshold, and reading it as one would be the exact error this instrument invites, because it is the one figure in the table that sits beside a substance with no capital route at all. The dossier states no other penalty for the row, so no term of years or fine is given here. Anyone comparing this row with the gabapentin and tramadol rows should note that those two carry Schedule 9 figures as well as Schedule 8 placements, and it is the Schedule 8 placement and not the figure that brings Article 58 into play for them.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: pregabalin is at Schedule 9, item 18, with 600 mg daily printed against it, and that figure is the most directly medicine facing fact the dossier carries for this row. The dossier does not state what the figure governs, whether a prescribing limit, a dispensing limit or something else, nor what procedure attaches to it, so it is reported here as printed and not interpreted. The permit question is deferred.
Documentation: Carry the prescription and the original dispensing packaging naming pregabalin, and note the daily dose, since the instrument prints 600 mg daily against this substance at Schedule 9, item 18. Provenance: the Schedule 9, item 18 placement and the entry «بريجابالين» were read on 20 September 2026, and the dossier records no Schedules 1 to 8 placement for pregabalin. Ask the health ministry what the 600 mg figure governs rather than assuming it is an amount a traveller may bring.

United Arab Emirates, Decision No. 158 of 2025, Schedule 9, item 18, printed entry «بريجابالين» for pregabalin with 600 mg daily stated, and no placement in Schedules 1 through 8 · Schedule 9 lies outside the schedules named by Articles 57 and 58, so neither attaches, and the printed daily quantity is a control limit rather than a capital threshold · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%A8%D8%B1%D9%8A%D8%AC%D8%A7%D8%A8%D8%A7%D9%84%D9%8A%D9%86 and the Schedule 9 text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D8%AC%D8%AF%D9%88%D9%84%20%D8%B1%D9%82%D9%85%209, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Pregabalin in United Arab Emirates, full detail →

Psilocybin

Legal status: Psilocybin is placed in Schedule 5 of Decision No. 158 of 2025 at the printed entry «بسيلوسيبين». The dossier draws the distinction that governs this subject in the United Arab Emirates: the compound is a scheduled Schedule 5 psychotropic, which is a different thing from the treatment of an unscheduled mushroom product considered only under the conduct based rule at Article 12(2). Those two routes produce different answers, and this row is the first of them. The entry names the compound, so a preparation proved to contain it is placed by it whatever the form of the material. The row runs through Articles 10, 41 and 57, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Schedule 5 is one of the four schedule groups Article 57 names, and the «بسيلوسيبين» entry is in Schedule 5, so the compound carries the harsher of the two trafficking articles. The dossier records Article 57 as stating mandatory death for its trafficking or promotion trigger and as stating no quantity for it, and records that the Schedule 10 bands do not gate that route. The contrast with the conduct based route is the thing to hold onto: a mushroom product that is not proved to contain the scheduled compound is a question for Article 12(2) and the non capital Article 44, while material proved to contain it is on this quantity free capital route. Article 41 carries the personal use route for this branch, with its tariff unstated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: psilocybin is in Schedule 5 at its own compound entry, and no medicinal product, clinical trial authorisation or prescribing route is recorded against it. Trials and approved treatment settings exist in other jurisdictions and the dossier extends nothing from them to this placement, so the question of any lawful route is deferred.
Documentation: No documentation route is recorded for psilocybin, and enrolment in a programme elsewhere is not an Emirati authorisation on this record. Provenance: the Schedule 5 placement and the entry «بسيلوسيبين» were read on 20 September 2026, with the capital analysis resting on Article 57 and not on the Schedule 10 bands. The point worth carrying is that the entry is the compound's, so what a product is called decides nothing and what it is assayed to contain decides everything.

United Arab Emirates, Decision No. 158 of 2025, Schedule 5, printed entry «بسيلوسيبين» for psilocybin, a compound entry distinct from the conduct based treatment of an unscheduled mushroom product under Article 12(2) · Articles 10, 41 and 57 attach to this branch and the Schedule 10 bands do not gate Article 57, which states no quantity · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%A8%D8%B3%D9%8A%D9%84%D9%88%D8%B3%D9%8A%D8%A8%D9%8A%D9%86 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2057, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Psilocybin in United Arab Emirates, full detail →

Synthetic Cannabinoids (K2 / Spice)

Legal status: Synthetic cannabinoids is a chemical class label rather than the name of one substance in the schedules, and that is the settled treatment of the label here. The dossier records «القنب الصناعي؛ الكانابينويدات الاصطناعية» as not being one chemical entry, so the Emirati result follows each proved constituent, checked against the complete schedules of Decision No. 158 of 2025. The class is the largest and fastest moving in this table, since new compounds appear continually and a class label covers whatever was made most recently as readily as what was made years ago. This instrument enumerates by substance, as its other cannabinoid searches show, and an enumerated schedule reaches the compounds it names and answers nothing about the rest. The determination was made on 20 September 2026.
Consequences if caught: Capital exposure: not established. That is a property of the label: each proved constituent must be classified first, and the constituent's schedule then determines whether Article 57, Article 58 or no capital route applies, so no label wide capital quantity can be stated. The spread is real on this class, because the dossier's cannabinoid searches record hexahydrocannabinol as a Schedule 1 entry with a quantity free Article 57 route and record other cannabinoid names as returning nothing at all. So two products both describable as synthetic cannabinoids can sit at opposite ends of that range, and the class word cannot distinguish them.
If prescribed / medical: No prescription question attaches to a chemical class label, because there is no entry for a prescription or a permit to evidence. The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule, which has no bearing here. Where a synthetic cannabinoid has a medicinal identity, the dossier's searches record dronabinol and nabilone as separately named substances, and any medical question belongs to the identified compound rather than to the class.
Documentation: There is nothing to document for a class label. Provenance: the constituent specific determination against the complete Decision No. 158 of 2025 schedules, recorded at «القنب الصناعي؛ الكانابينويدات الاصطناعية», was made on 20 September 2026. The practical point is that herbal material sprayed with one of these compounds carries no reliable indication of which one, and since the answer follows the compound, only an analysis produces a question that can be answered.

United Arab Emirates, Decision No. 158 of 2025, complete schedules · constituent specific determination for the chemical class label recorded at «القنب الصناعي؛ الكانابينويدات الاصطناعية», which the dossier records as not being one chemical entry · each proved constituent is classified first and its schedule then determines whether Article 57, Article 58 or no capital route applies, so no label wide capital quantity can be stated · the dossier's cannabinoid searches record hexahydrocannabinol as a Schedule 1 entry and dronabinol and nabilone as separately named substances, while other cannabinoid names returned nothing · read at https://sha.shj.ae/#:~:text=%D8%A7%D9%84%D8%AC%D8%AF%D8%A7%D9%88%D9%84%20%D8%A7%D9%84%D9%85%D8%B1%D9%81%D9%82%D8%A9 · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Synthetic Cannabinoids (K2 / Spice) in United Arab Emirates, full detail →

Tobacco

Legal status: Tobacco is not a narcotic or psychotropic substance under the federal drug schedules. The dossier ran a completed non reach search across Schedules 1 to 9 of Decision No. 158 of 2025 for «التبغ» and recorded no entry, with a separate tobacco control framework governing instead. This row is the leaf and the products made from it, where the nicotine row in the same table is the alkaloid, and both fall outside the drug schedules for the same reason: neither is a scheduled narcotic or psychotropic. The dossier does not record the terms of the tobacco control framework, so nothing here is said about age limits, product standards, taxation or where smoking is permitted. The search was run on 20 September 2026.
Consequences if caught: Capital exposure: none. Decision No. 158 of 2025 Schedules 1 to 8 do not reach tobacco, so Articles 57 and 58 do not attach and no narcotics quantity applies. Whatever the tobacco control framework provides is a separate regime and not a narcotics capital provision, and the dossier does not record what it provides. The distinction worth keeping is that a control framework of that kind typically regulates sale, advertising and place of use rather than criminalising possession, which is a structurally different thing from the schedule placements that govern the rest of this table.
If prescribed / medical: No narcotics prescription question arises for tobacco, because it is outside Decision No. 158 of 2025 and there is no drug authorisation to obtain. The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule, which does not affect this row. Anything a traveller needs here belongs to customs and tobacco control rules rather than to the drug law, and the dossier records neither.
Documentation: No drug law documentation applies to tobacco. Provenance: the completed Schedules 1 to 9 non reach search on «التبغ» was run on 20 September 2026. Duty free allowances and product restrictions are the live questions for a traveller and they sit with customs and the tobacco control framework, which the dossier does not describe, so they should be checked against a current official source rather than inferred from this cell.

United Arab Emirates, Decision No. 158 of 2025, completed Schedules 1 to 9 non reach search for «التبغ», tobacco, returning no narcotic or psychotropic entry, with a separate federal tobacco control framework governing instead and its terms not recorded in the dossier · the schedules were read at https://sha.shj.ae/#:~:text=%D8%A7%D9%84%D8%AC%D8%AF%D8%A7%D9%88%D9%84%20%D8%A7%D9%84%D9%85%D8%B1%D9%81%D9%82%D8%A9 and the federal instrument at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D8%AA%D8%A8%D8%BA, the federal legislation portal · the instrument is written in Arabic and the English renderings are the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Tobacco in United Arab Emirates, full detail →

Tramadol

Legal status: Tramadol appears twice in Decision No. 158 of 2025. It is placed at Schedule 8, item 79, at the printed entry «ترامادول» with the chemical name the dossier renders as (+/-)cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, and it appears again at Schedule 9, item 20, where the instrument states route specific quantities of 600 mg intravenous and 400 mg oral or rectal. The Schedule 9 figures are the most detailed medicines quantities the dossier carries for any row in this table, and they are separate from the penalty architecture: Schedule 8 is the placement that carries the articles, and Schedule 9 records quantities. Tramadol is the single most commonly encountered controlled analgesic among travellers to the region, which is why the double listing matters in practice. The row runs through Articles 11, 43 and 58, with Schedule 10 group 3 carrying the penal band. The placements were read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and tramadol's controlling placement is Schedule 8, item 79, so the article applies to the row. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary rather than mandatory, and it records that the article states no quantity. None of the figures attached to this substance is a capital threshold: the Schedule 9 route specific quantities of 600 mg intravenous and 400 mg oral or rectal are medicines quantities, and the Schedule 10 group 3 band does not gate Article 58. Three numbers and three purposes sit on this one row, and the capital route uses none of them. Article 43 carries the personal use route, with its tariff unstated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: tramadol is at Schedule 8, item 79, and Schedule 9, item 20 states 600 mg intravenous and 400 mg oral or rectal. Those figures are route specific, which tells you they are about administration rather than about carriage, but the dossier does not state what they govern or what procedure attaches to them, so they are reported here as printed quantities and not interpreted as a traveller allowance. The permit question is deferred.
Documentation: Carry the prescription and the original dispensing packaging naming tramadol, with a physician's letter giving the daily dose and the route, since the instrument states route specific quantities at Schedule 9, item 20. Provenance: the Schedule 8, item 79 placement, the Schedule 9, item 20 figures of 600 mg intravenous and 400 mg oral or rectal, and the entry «ترامادول» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative. Do not treat either Schedule 9 figure as an amount that may be brought in without asking the health ministry what it governs.

United Arab Emirates, Decision No. 158 of 2025, Schedule 8, item 79, printed entry «ترامادول» for tramadol with the chemical name rendered as (+/-)cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, and separately Schedule 9, item 20, stating 600 mg intravenous and 400 mg oral or rectal · Articles 11, 43 and 58 attach to the Schedule 8 placement, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and neither the Schedule 9 figures nor the Schedule 10 group 3 band is a capital threshold · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%AA%D8%B1%D8%A7%D9%85%D8%A7%D8%AF%D9%88%D9%84 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English renderings are the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Tramadol in United Arab Emirates, full detail →

Xanax (Alprazolam)

Legal status: Alprazolam is individually scheduled in Schedule 8 of Decision No. 158 of 2025, the branch the dossier describes as the psychotropic Schedule IV equivalent, at the printed entry «ألبرازولام». The dossier's finding on this row is that the benzodiazepine class label is not the legal unit of control here: the schedule names alprazolam itself, and the six benzodiazepines carried in this table are each named separately in the same schedule. So the placement rests on the individual entry and not on a class rule, and a benzodiazepine the schedule does not name is not placed by this row. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and alprazolam is in Schedule 8, so a widely prescribed anxiolytic is inside a capital trafficking article. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary rather than mandatory on this row, and it records that the article states no quantity. The Schedule 10 bands do not gate that route. The distance between the ordinariness of the medicine and the severity of the article is the finding: Schedule 8 is the lowest of the psychotropic schedules and it is still inside Article 58, so placement low in the scheduling does not put a substance outside the capital provision. Article 43 carries the personal use route for this branch, with no tariff stated in the dossier.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: alprazolam is individually named in Schedule 8, so a traveller's prescription describes a substance that the schedule reaches by name and not by class. The dossier records no prescribing route, no traveller quantity allowance and no import permit procedure for the Schedule 8 branch, so what a foreign prescription achieves at the border is the question it does not answer, and it is deferred.
Documentation: Carry the prescription and the original dispensing packaging naming alprazolam as the active ingredient, together with a physician's letter, and put the permit question to the health ministry before travelling because no Emirati procedure is recorded here. Provenance: the Schedule 8 placement and the entry «ألبرازولام» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative rather than on the Schedule 10 bands. Loose tablets in a pill organiser are the common form of this problem, since they separate the medicine from the label that identifies it.

United Arab Emirates, Decision No. 158 of 2025, Schedule 8 (psychotropic Schedule IV equivalent), printed entry «ألبرازولام» for alprazolam, individually named rather than reached by a benzodiazepine class rule · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 bands do not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%A3%D9%84%D8%A8%D8%B1%D8%A7%D8%B2%D9%88%D9%84%D8%A7%D9%85 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Xanax (Alprazolam) in United Arab Emirates, full detail →

Zolpidem

Legal status: Zolpidem is individually controlled in Schedule 8 of Decision No. 158 of 2025, at the printed entry «زولبيديم». The dossier's finding is that it is not an ordinary unscheduled sleep medicine under the federal drug law, and that is the fact most likely to surprise a traveller: zolpidem is an imidazopyridine rather than a benzodiazepine, it is dispensed very widely, and it is nonetheless named in the same schedule as the six benzodiazepine members in this table. The entry names the substance, so the placement does not depend on any structural relationship to that class. The row runs through Articles 11, 43 and 58, with Schedule 10 carrying the quantity bands. The dossier states the content of Article 58 and does not state what Articles 11 and 43 provide. The placement was read on 20 September 2026.
Consequences if caught: Article 58 reaches Schedules 3, 6, 7 and 8, and zolpidem is in Schedule 8, so a common hypnotic is inside a capital trafficking article. The dossier records Article 58 as providing death or life imprisonment as alternatives for its stated trafficking or promotion trigger, so death is discretionary rather than mandatory, and it records that the article states no quantity. The Schedule 10 bands do not gate that route. Sleeping tablets are the medicine travellers most often carry loose, share with a companion or pack without the original box, and each of those habits removes the link between the tablet and the prescription while the schedule entry stays where it is. Article 43 carries the personal use route, with its tariff unstated.
If prescribed / medical: The dossier records at the modafinil row that a 268 entry ministry travellers list was checked and expressly not used as a schedule. Attached to this substance: zolpidem is named individually in Schedule 8, so a prescription for it evidences a substance the schedule reaches by name. No prescribing route, traveller allowance or permit procedure is recorded for the branch, so the question of what documentation suffices on arrival is deferred rather than answered.
Documentation: Carry the prescription and keep the tablets in the original labelled packaging rather than in a pill organiser, because the label is what connects this medicine to the prescription that authorises it. The dossier records no Emirati permit procedure, so those documents are evidence rather than an authorisation and the permit question belongs with the health ministry before departure. Provenance: the Schedule 8 placement and the entry «زولبيديم» were read on 20 September 2026, with the capital analysis resting on Article 58 and its death or life alternative.

United Arab Emirates, Decision No. 158 of 2025, Schedule 8, printed entry «زولبيديم» for zolpidem, an imidazopyridine named individually in the same schedule as the six benzodiazepine members in this table · Articles 11, 43 and 58 attach to this branch, Article 58 giving death or life imprisonment as alternatives with no quantity stated, and the Schedule 10 bands do not gate it · the schedule text was read at https://sha.shj.ae/#:~:text=%D8%B2%D9%88%D9%84%D8%A8%D9%8A%D8%AF%D9%8A%D9%85 and the article text at https://uaelegislation.gov.ae/ar/legislations/1540#:~:text=%D8%A7%D9%84%D9%85%D8%A7%D8%AF%D8%A9%2058, the federal legislation portal · the instrument is written in Arabic and the English rendering is the dossier's · read as at 20 September 2026 · Updated September 21, 2026

Zolpidem in United Arab Emirates, full detail →

Not individually verified

19 substances are not individually verified for United Arab Emirates

For these the governing national drug law is cited, but we have not verified that the substance specifically is scheduled under it. Treat them as unanswered, not as legal. Confirm with United Arab Emirates’s drug authority or your embassy.

Substance	What we found
1P-LSD	Not confirmed. No entry matching 1P-LSD was found in the complete schedules of Decision No. 158 of 2025 after an...
2C-T-7	Not confirmed. No entry matching 2C-T-7 was found in the complete schedules of Decision No. 158 of 2025 after an...
3-MMC	Not confirmed. No entry matching 3-MMC was found in the complete schedules of Decision No. 158 of 2025 after an...
7-Hydroxymitragynine (7-OH)	Not confirmed. No entry matching 7-hydroxymitragynine was found in the complete schedules of Decision No. 158 of...
Barbiturates	Not confirmed. Barbiturates is a class label, and the member by member check that answers such a label was run...
Cannabinol	Not confirmed. No entry matching cannabinol was found in the complete schedules of Decision No. 158 of 2025 after an...
CBD	Not confirmed. No entry matching cannabidiol was found in the complete schedules of Decision No. 158 of 2025 after a...
DXM	Not confirmed. No entry matching dextromethorphan was found in the complete schedules of Decision No. 158 of 2025...
Ephedrine	Not confirmed. No entry matching ephedrine was found in the complete schedules of Decision No. 158 of 2025 after a...
Kratom	Not confirmed. Neither the plant name nor the trade name was found in the complete schedules of Decision No. 158 of...
LSA (Morning Glory)	Not confirmed. No entry matching ergine was found in the complete schedules of Decision No. 158 of 2025 after a...
Memantine	Not confirmed. No entry matching memantine was found in the complete schedules of Decision No. 158 of 2025 after an...
Modafinil	Not confirmed. No entry matching modafinil was found in the complete schedules of Decision No. 158 of 2025 after...
Phenibut	Not confirmed. No entry matching phenibut was found in the complete schedules of Decision No. 158 of 2025 after...
Quetiapine	Not confirmed. No entry matching quetiapine was found in the complete schedules of Decision No. 158 of 2025 after...
Salvia divinorum	Not confirmed as the plant. No entry matching Salvia divinorum was found in the complete schedules of Decision No....
Scopolamine (Devil's Breath)	Not confirmed. No entry matching scopolamine was found in the complete schedules of Decision No. 158 of 2025 after...
THC-P	Not confirmed. No entry matching this cannabinoid was found in the complete schedules of Decision No. 158 of 2025...
Xylazine	Not confirmed. No entry matching xylazine was found in the complete schedules of Decision No. 158 of 2025 after...

Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.

Before you travel

Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.

If you’re detained or arrested abroad

Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →

← All countries Drug index